← All companies

Constellation Software

CSU.TOToronto Stock ExchangeCADVertical-market softwareReviewed Nov 15, 2026

Software cash and acquisition compounding

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts · TTM September 2026 and 30 September balances; post-September commitments disclosed 6 November; 26 October FX and exits unchanged

Recurring specialist software cash funds a decentralized acquisition engine. Customer durability, capital deployment, purchase yields and ownership claims determine per-share compounding.

  • Recurring organic growth and customer retention, especially Altera
  • Acquisition cash yields and deployment capacity at increasing scale
  • IRGA/Joday claim, minority ownership, debt service and subsidiary cash restrictions
Inspect live quotes, sensitivity grid & cash-flow bridge

Scenario assumptions

Software cash and acquisition compounding · TTM September 2026 and 30 September balances; post-September commitments disclosed 6 November; 26 October FX and exits unchanged

DriverDownsideBaseUpside
Exit / common operating cash after financing15.00×20.00×25.00×
Annual share dilution0.0%0.0%0.0%
Available cash deployment fraction50.0%100.0%100.0%
Organic revenue growth
Year 1: 0.0%
Years 2–5: -2.0%
Year 1: 1.5%
Years 2–3: 2.0%
Years 4–5: 3.0%
Year 1: 2.5%
Years 2–5: 4.0%
Owner-cash margin on organic revenue
Year 1: 17.5%
Years 2–5: 16.5%
Years 1–5: 17.5%
Years 1–3: 17.5%
Years 4–5: 18.0%
Price paid per unit of acquired revenue
Years 1–5: 1.50×
Years 1–5: 1.17×
Years 1–5: 1.17×
Owner-cash margin of acquired businesses
Years 1–5: 12.0%
Year 1: 15.0%
Years 2–3: 16.5%
Years 4–5: 17.8%
Year 1: 16.0%
Years 2–5: 17.8%
Acquired revenue growth after purchase
Years 1–5: -2.0%
Year 1: 1.5%
Years 2–3: 2.0%
Years 4–5: 3.0%
Year 1: 2.5%
Years 2–5: 4.0%
Deal budget (capital available for acquisitions)
Year 1: 1,879.35
Years 2–3: 680.20
Years 4–5: 1,879.40
Year 1: 2,315.11
Year 2: 2,384.60
Year 3: 2,456.10
Year 4: 2,529.80
Year 5: 2,605.70
Year 1: 3,465.58
Years 2–3: 3,716.60
Years 4–5: 4,516.10
  • Downside case. Stress 2% annual erosion of the existing cash base, deploy only half the available surplus, earn an 8% mature purchase cash yield and exit at 15x. This tests weaker retention, Altera pressure, poorer deal economics and a shorter runway; retained cash remains an asset. It is not a default scenario.
  • Base case. Latest group organic growth is 1% after FX. Continue current ongoing spending and flat dividends; deploy surplus into cash-funded acquisitions at the group's achieved 2020–2025 aggregate acquisition cash yield. Exit at a chosen 20x operating equity cash multiple, with investments and all retained claims added/deducted separately.
  • Upside case. Use 3% existing cash growth, full cash deployment, the achieved 15.1% aggregate purchase cash yield (no better-than-record deal prices) and a 25x exit. Requires resilient customer economics and continued sourcing discipline. No margin expansion, new leverage or rerating of retained investments is credited.

Research notebook

Reviewed Nov 15, 2026

8 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts
Business model

USD millions unless stated. Facts are in financials/facts.json; named arithmetic (prefixes snap, seg, ue) is in valuation/calculations.json as audit steps that do not feed the model. Sources: FY2025 shareholder report (csi-fy2025), FY2022 and FY2023 reports, Q2 2026 report (csi-q2-2026), the 2015 and 2021 letters (csi-2015-letter, csi-2021-capital).

Constellation (CSU) owns a large number of specialist software businesses (the reports read give no count) serving narrow workflows: municipalities, transit, utilities, hospitals, clubs, banks, media, construction and so on. Six operating groups (Volaris, Harris, Topicus, Vela, Jonas, Perseus) are aggregated into one reportable segment because each "operates essentially as a mini Constellation" (FY2025 note 23). Topicus (Europe) and Lumine (communications and media) are separately listed and consolidated through super-voting shares. Common shares trade in CAD; reports are in USD.

Value-creation mechanism

Buy, hold forever, and recycle the cash. A vertical-market software (VMS) business is bought for a price close to a small multiple of its after-tax cash; the customer keeps paying maintenance because replacing mission-critical software means data migration, retraining and operational risk; head office and the operating group impose cost discipline and best-practice benchmarking; the business's surplus cash is then sent back (or kept, under the "keep your capital" rule) and spent on the next purchase. The step where most value is created is the purchase price. CSU's own analysis of every acquisition since 2004 found that the revenue multiple paid was a far more obvious driver of IRR than post-acquisition organic growth (2015 letter, pp.5-6). Integration and margin repair matter (Altera below), but the edge is paying a price that a permanent, decentralized owner can justify and a leveraged buyer flipping in three to seven years usually cannot (2021 letter). The second step, recycling, works because the businesses need almost no tangible capital: customers prepay, so organic growth is funded by customers, and nearly all reinvestment goes into the next acquisition.

Business-model profile

Comparable firms are chosen by these traits, not by the industry label.

Growth vehicle: Acquisitions. Revenue rose from 3,969 in FY2020 to 11,623 in FY2025, about 24% a year, while FX-adjusted organic growth was 3% in FY2025 (5% for recurring revenue). Acquisition cash was 1,847, 1,683 and 1,513 in FY2023–FY2025, 16.8% of revenue. So roughly three points of growth a year come from the installed base and the rest is bought. The model therefore buys revenue every year at a measured price and grows the existing businesses separately at the installed-base rate; organic growth alone would describe a low-growth software company that CSU is not.

Capital intensity: 0.6% of sales, asset-light. Capital spending is about 0.6% of revenue: offices and hardware for staff who write and maintain vertical-market software. Tangible capital including leases is negative (−982 in FY2025) because customers prepay maintenance (deferred revenue of 70 days). The capital that drives growth is acquisition cash, about 17% of revenue a year, not capex.

Comparables. A comparable firm buys many small businesses every year with internally generated cash, needs almost no capital spending, and earns mostly recurring maintenance revenue (75% of FY2025) from customers who rarely replace mission-critical systems. Its constraint at this scale is finding enough deals at its price, so comparables are serial acquirers of small asset-light businesses, not software product companies. Not the label: "Software" suggests product-led organic growth valued on software multiples; CSU buys its growth and grows about 3% a year organically.

Declared in valuation/model.json (businessProfile). npm run check measures deal and capital intensity from the reported facts, and the outside view grades the forecast only against firms that share them.

Economic snapshot

FY2025, consolidated, reported definitions unless marked. EBITA here is revenue less operating expenses including depreciation (so leases are capitalized), before acquired-intangible amortization, FX, IRGA revaluation, finance items and impairments.

MeasureFY2025Definition / source step
Revenue11,62375% maintenance and other recurring (8,700); licenses 415; services 2,126; hardware 382
Direct margin67.7%Revenue less hardware cost, third-party costs and maintenance and services staff (CSU reports no gross margin)
EBITA margin26.5%snapEbitaMargin2025; 28.4% in FY2020 (snapEbitaMargin2020)
Incremental EBITA margin36.6% FY2024→25; 25.5% FY2020→25snapIncrementalMargin2025; acquired businesses enter at their own (often lower) margins
R&D staff / revenue13.9%14.3-14.6% in every year 2020-2024 (facts csuRdStaff*)
Receivables + unbilled60 days of revenue1,920
Deferred revenue70 days of revenue2,214
Net operating working capital(1,607)snapWorkingCapital2025; customers fund the business
PP&E + right-of-use assets625241 + 384
Tangible capital incl. leases(982)snapTangibleCapital2025
Intangibles incl. goodwill, net / at cost8,388 / 15,157goodwill at cost 1,815
Debt / leases / IRGA claim / holdbacks4,131 / 423 / 1,233 / 432debt 1,489 recourse to CSI, 2,642 non-recourse
Cash3,0891,172 held where upstream distribution is restricted
NOPAT, leases expensed2,455snapNopat2025: EBITA less current tax (606) and lease interest (16)
Return on tangible capitalnot meaningfultangible capital is negative
ROCE on amortized capital36.9%snapRoceAmortized, average capital 6,661
ROCE on acquisition cost19.3%snapRoceGross, average capital 12,688

Normalization. Capex (68) roughly equals PP&E depreciation (total depreciation 201 less lease principal 131 ≈ 70), so no sustaining-capital adjustment is needed. Recently acquired businesses are only partly in FY2025: Cipal Schaubroeck alone was missing 49 of revenue (pro forma 11,672 vs 11,623). Minorities took 243 of the 1,926 pre-NCI FCFA2S (12.6%). The model's common-owner bridge (stage 7, research/07-assumption-register.md) handles these; this snapshot is the consolidated base it explains.

What the snapshot says. Return on tangible capital is meaningless for CSU: the business runs on customers' money, so the only capital that matters is the price paid for each business. Measured against that price (intangibles at cost), the portfolio earns about 19% after tax, well below the 37% on amortized book that flatters any accounting ROIC. That 19% blends decades-old purchases earning far above cost with recent ones earning less; the marginal return is measured separately (stage 6: 15.1%).

Economic segmentation

The reported segment table is one line. Re-cut by how value is created, using the supplemental Topicus, Lumine and Altera disclosures (FY2025 MD&A, PDF pp.15-17) and CSU's economic ownership (segLookThroughCfo, operating cash before interest, at accounting ownership):

Economic unitFY2025 revenueOperating cashCSU shareLook-through cashShareDemand driver and trend
Core small and mid VMS (CSU ex Topicus, Lumine, Altera)8,4001,930~100%1,93078%Installed-base maintenance and price; FX-adjusted organic 5% recurring, 3% total in FY2025. Growing slowly, acyclical
Topicus (European VMS)1,74644860.65% deemed27211%Dutch and European public sector, education, health; organic 4% total, 7% recurring. Growing; CSU's direct stake is ~31% plus the IRGA purchase claim
Lumine (communications and media)76623661.4%1456%Telecom and broadcast software; organic 0%. Larger carve-outs (WideOrbit 2023, Synchronoss 2026)
Altera (hospital EHR carve-out, 2022)712117100%1175%Hospital IT budgets; revenue down 16% since purchase; recurring −3% FY2025, −19% Q2 and −8% Q3 2026; 9M 2026 revenue 445, 4% of group. Declining
Financial stakes (Asseco, other)—dividends 69 in H1 2026—outside—Valued separately at fair value (Asseco 1,092 group, September 2026)

So about four-fifths of CSU's owner cash comes from the small and mid VMS engine whose economics are described above. The large carve-outs (Altera, Optimal Blue, WideOrbit, Synchronoss) are a different mechanism: buy a neglected division cheaply relative to revenue, cut cost to group norms and accept shrinking revenue. They are a growing share of capital but not yet of cash. Profit by revenue type is even more concentrated (unit economics below): recurring maintenance earns roughly 85% of EBITA on 75% of revenue.

Revenue share is not profit share here: licenses and services were 22% of revenue but about 13% of EBITA, and they are the cyclical, discretionary part (licenses −8% and services −4% FX-adjusted organic in FY2025, while recurring grew 5%).

Unit economics

The unit through which CSU adds value is an acquired VMS business. Two views: a revenue-type P&L that shows where the profit sits inside every business, and observed deals that show what CSU pays and earns.

Inside the unit: profit by revenue type, FY2025 (allocations are estimates; ue* steps). Third-party costs (1,114) are allocated by software revenue; all R&D staff (1,615) is charged to recurring revenue, the adverse choice for that line; shared overhead (S&M 702, G&A 1,181, occupancy, travel/telecom/software, professional fees, other and depreciation: 3,175 in total) is allocated by revenue.

RecurringServicesLicensesHardwareTotal
Revenue8,7002,12641538211,623
Direct staff (maintenance, services)(1,223)(1,202)——
R&D staff(1,615)———
Third-party / hardware cost(862)(211)(41)(217)
Contribution5,000 (57%)713 (34%)374 (90%)165 (43%)6,252
Shared overhead by revenue(2,377)(581)(113)(104)(3,175)
EBITA2,623 (30%)133 (6%)261 (63%)61 (16%)3,077
Share of EBITA85%4%8%2%

Capital per unit is the purchase price. Working capital is negative (deferred revenue exceeds receivables), PP&E is about 2% of revenue and capex matches depreciation. At the group's 2025 unlevered owner-cash margin (21.7% of revenue: operating cash after tax, leases and capex) and the measured 6.61x gross purchase multiple (stage 6; 6.57x at entry on net capital in the current model), a typical acquired business costs about 1.4x revenue and earns about 15% after tax on that price once integrated.

Observed units (FY2022, FY2023 and FY2025 acquisition notes; annual revenue from the issuer's pro forma figures):

DealPriceAnnual revenue at purchasePrice / revenueProfit at purchaseLater evidence
Altera (Allscripts hospitals carve-out, May 2022)7278460.86xnet income 0 in first 8 monthsFY2025 FCFA2S 92 (12.7% of price; 12.9% in FY2023) on revenue 712 (−16%)
WideOrbit (Feb 2023, via Lumine)504 incl. special shares1722.9xnet income 1 in 2023not separately disclosed
Optimal Blue (Sep 2023)7051873.8xnet income 0 in 2023not separately disclosed
Cipal Schaubroeck (Jun 2025)2581222.1xnet loss 6 in 7 months—
Synchronoss (Feb 2026, via Lumine)309 cash~169 (Q2 x4)1.8xpost-close losseslumine-q2-2026-fs

Before and after the intervention. Every disclosed large deal arrives at roughly zero profit and is bought at 0.9-3.8x revenue; the group's acquired cash yield of about 15% means CSU lifts these units toward a cash margin of 15-25% of revenue. Altera is the cleanest case: a carve-out that earned nothing for Allscripts became a business producing about 13% FCFA2S on its price within a year, by cost restructuring (expenses were 558 on 712 of revenue in FY2025, 78%, against 73% for the group).

The failure, or the limit of the levers. The same Altera shows what cost discipline cannot do: revenue fell from about 846 to 712, professional services fell 16% organically in FY2025 and recurring revenue fell 19% in Q2 2026, partly against one-off prior-year contract revenue. A 12.7% levered yield on a shrinking base is below the group aggregate and below CSU's historical small-deal returns. The large-deal practice that the 2021 letter announced (lower hurdles for multi-hundred-million cheques) therefore produces lower and more fragile returns, as Leonard predicted.

Independent checks

  1. Group accounts against the unit model. Recurring revenue of 8,700 with maintenance and R&D staff of 2,838 implies a 33% staff ratio; group staff expense is 51% of revenue, and the gap is services, S&M and G&A, consistent with the allocation. The unit model's 30% recurring EBITA margin and 6% services margin sum exactly to the reported 3,077 EBITA (the allocation reconciles by construction; the test is that no line goes negative under reasonable keys).
  2. Adverse allocation. Charge all 3,175 of shared overhead to recurring revenue: recurring EBITA falls to 1,825, still 59% of the total, and services and licenses together would be 35%. Charging part of R&D to licenses (new products) would raise recurring's share. The conclusion that the installed-base maintenance stream is the profit pool survives every allocation tried.
  3. Implied price against observed prices. The aggregate 6.61x cash multiple on gross capital (6.57x at entry on net capital since the 3 November reconciliation) implies about 1.4x revenue at group margins. Observed large deals were 0.9-3.8x revenue at near-zero margins. CSU pays more per dollar of revenue for businesses whose margins it expects to raise, and less for shrinking ones (Altera). That is consistent with the 2015 letter's finding that the revenue multiple drives IRR.
  4. Impairment testing. Goodwill and intangibles are tested against revenue multiples of recurring revenue for each business unit (FY2025 note 10). FY2025 impairments were 43 on 15,157 of intangibles at cost (0.3%; 28 in FY2024). Few acquired units have failed badly enough to be written down, although this test is lenient by design.
  5. Group ROCE against marginal return. 19.3% on all acquisition cost against 15.1% measured on 2021-2025 deals (stage 6): the newer capital earns less than the stock, as expected when hurdles were lowered for larger deals.

Where the consensus disagrees. The market's live debate (2025-2026 commentary) is whether AI-assisted development lets cheap competitors replace these products, which would hit the recurring line that carries 85% of profit. The unit model says that is the right place to worry and that services and license weakness, which the market sees first, matters little to cash. The observation that would settle it is FX-adjusted recurring organic growth excluding Altera (4% in Q2 2026) and attrition commentary in the Q3 2026 MD&A on 6 November and following quarters; a move below about 0% for several quarters would mean the profit pool itself is shrinking.

Q3 2026 check — 6 November 2026

Q3 confirmed the economics above rather than changing them. Recurring revenue outside Altera grew 4% after FX (Q2: 4%), 5% outside US healthcare and Altera, 7% at Topicus and 3% in the CSU core. Licenses (−17%) and services (−5%) kept shrinking, so group organic growth was 2%. Altera's recurring decline narrowed to −8% (Q2 −19%), with sizable client departures expected to run until the end of 2027. CSU also bought two US healthcare businesses whose very high customer attrition it says it modeled into the price, a reminder that the purchase yield, not the target's growth, is the decision variable. Source: Q3 MD&A pp.4–5, 16–17.

History, demand and counterparties

USD millions unless stated.

CSU learned to compound through many small software acquisitions, then delegated capital allocation to its operating groups as it grew. The 2015 letter (csi-2015-letter, pp.2-9) reported ROIC rising from 21% (2006) to 38% (2015) with organic net revenue growth between −3% and 8% a year, and warned that larger deals at lower hurdles would pull returns down. In February 2021 (csi-2021-capital) Leonard stopped special dividends, lowered hurdles for "very large" VMS deals and began investing outside VMS; Altera (2022), Optimal Blue and WideOrbit (2023), the Asseco stake (2025) and Synchronoss (2026) followed. The Topicus (2021) and Lumine (2023) spin-outs created listed subsidiaries with minority holders, so per-share earning power needs an ownership bridge before comparing years. Leonard resigned as President on 25 September 2025 and Mark Miller replaced him (csi-mic-2026, p.14). No external CSU thesis was supplied; this study reconstructs reported definitions and builds its own current estimates.

Demand drivers and cycle

Who uses, who pays, who decides. The end user is a clerk, dispatcher, nurse, loan officer or club manager running a daily workflow. The payer is usually an institution's operating budget (a municipality, transit authority, hospital, bank or private SME), and the decision-maker is a department head or IT director who personally bears the risk of a failed replacement. That asymmetry matters: the person who could save money by switching is the person who would be blamed for an outage, so incumbency is protected beyond what price alone would suggest. No customer exceeds 5% of revenue (FY2025 note 23), and a large share of receivables is with public-sector governments (FY2025 note 21).

Demand by type (FY2025 revenue 11,623, csi-fy2025 PDF p.5):

TypeRevenueShareFX-adjusted organic FY2025Character
Maintenance and other recurring (support, SaaS, hosting, transactions)8,70075%+5%Replacement-like: the installed base renews; price increases and module adds drive growth
Professional services2,12618%−4%Implementations and projects: growth- and discretionary
Licenses4154%−8%New customers and new modules: growth, discretionary
Hardware and other3823%+4%Pass-through, discretionary

Regulation drives part of recurring demand (tax and reporting rule changes in public-sector and health software must be implemented each year) but is not separately disclosed.

The cycle, measured. The 2015 letter's table shows organic net revenue growth of −3% in 2009 and −2% in 2010, against ROIC that stayed at 24-26% (csi-2015-letter p.2). In the Covid quarter (Q2 2020) FX-adjusted organic revenue fell 7%, but licenses fell 28% and maintenance and recurring only 1%; recurring was back to +2% by Q4 2020 (csi-fy2021-mda, quarterly organic table). In 2024-2025 licenses swung between −22% and +17% by quarter while recurring stayed at +4% to +6% every quarter (FY2025 report p.5). The recurring stream is close to acyclical; the cyclical part is small and low-margin (stage 3: services and licenses about 13% of EBITA).

The market misperception being tested. Since late 2025 the market has priced the fear that AI-assisted development lets cheaper competitors replace incumbent vertical software or forces price cuts (the stock fell from about C$5,000 in mid-2025 to C$2,196 at its 52-week low, csu-price-history-2026-11-03). The series that tests it is FX-adjusted recurring organic growth, especially outside Altera: 5% in FY2025, 2% in Q2 2026 for the group and 4% excluding Altera, whose recurring revenue fell 19% (csi-q2-2026, MD&A pp.5 and 16). So far the data show deceleration concentrated in one acquired business with a known contract issue, not broad erosion. That is not evidence the fear is wrong; AI substitution, if it comes, would appear first in new-customer wins and then in renewals, and four quarters of data cannot rule it out.

Competition

Competition happens in two separate markets.

For customers, inside each micro-vertical. Each business typically faces a handful of specialist rivals in its niche and country plus horizontal platforms (ERP, CRM, low-code) at the edges. In US public-sector software the largest specialist is Tyler Technologies; in several niches Roper's software businesses compete; in Europe the rivals are mostly local private firms. Share by niche is not disclosed and was not estimated. The number of competitors per niche has historically been stable because niches are too small to attract large entrants. The advantage, in one sentence: the incumbent's software holds the customer's data and procedures, so a rival must offer enough to justify a risky migration that the buyer's decision-maker gains little from. Evidence it is durable: recurring revenue grew organically in every quarter of 2024-2025 and fell only 1% in the Covid trough, while CSU kept R&D at 14-15% of revenue to maintain the products. The competitor that could hurt CSU is not a named firm but an AI-native vendor that cuts the cost of building and of migrating to a replacement; it hasn't yet because the binding constraint is the customer's risk and data conversion, not the cost of writing code.

For acquisitions. Sellers choose among private-equity buyers, strategic acquirers (Roper, Tyler, other serial VMS buyers) and CSU's own groups, including Topicus and Lumine. Leonard's description (csi-2021-capital): 40-70 "large" VMS businesses are sold each year, mostly through fewer than a dozen brokers; CSU knew of about 80% of them over five years but was invited into only 16% of processes, and most competitors maximize leverage and resell within three to seven years. CSU's advantage in small deals is a proprietary, relationship-sourced pipeline built over 30 years and a promise of permanent ownership; in large deals it has none, which is why it lowered hurdles to be invited. The competitor that could hurt is private equity with cheap debt bidding up prices; when rates were near zero (2021-2022) CSU's deployment still rose (1,337 → 1,782), so the measured 2021-2025 yield of about 15% was earned against that competition.

Counterparty incentives

CounterpartyWhat they wantWhat CSU givesTheir outside optionWhat would change the arrangement
Customers (municipalities, hospitals, SMEs)Software that keeps working, compliance updates, predictable cost, no failed projectsContinuity, maintained products (R&D 13.9% of revenue), modest annual price increasesReplace via a tender or project: migration, retraining, risk to the decision-makerCheaper migration (AI-assisted conversion), a modern product the users demand, or aggressive price increases that make a project worth the risk. Altera shows hospitals do leave or cut scope when a product falls behind
Founders and corporate sellersFounders: a permanent home that keeps staff and brand; corporate parents (Allscripts for Altera): speed and certainty for a non-core unitBuy-and-hold, autonomy for the business-unit manager, quick closePrivate equity at a higher price with a later resale; a strategic buyerIf CSU's permanent-owner reputation weakened (forced resales, centralization) it would have to pay auction prices
M&A brokersCompetitive auctions and feesLower hurdles on large deals so CSU bidsExclude CSU from processes (they did, per the 2021 letter)More CSU wins at auction prices would raise invitations but lower returns
Business-unit and operating-group managersBonus and wealthBonus on ROIC (net of a 5% rate) and net revenue growth; 75% of after-tax bonus in escrowed shares (csi-mic-2026 pp.12-14)Leave for PE-backed rivals (one-year non-competes)A change to the bonus plan; Leonard noted it took years to rebuild trust after the 2011 sale attempt (csi-2015-letter p.7)
Joday Group (Topicus founders' holding)Liquidity and value for its Topicus Coop unitsIRGA/membership agreement: CSU must buy the units at a formula tied to Topicus recurring revenue, net assets and investment prices (csi-2021-ownership)Hold; the agreement sets exercise windowsThe claim (1,186 at June 2026) grows with Topicus; the model carries it separately
Topicus and Lumine minority holdersPer-share value of their listed stockAccess to CSU's method; CSU keeps 50.1% votes through a super-voting shareSell their sharesThey cannot change control; their claim is in NCI (243 of FY2025 pre-NCI FCFA2S)
Lenders (non-recourse subsidiary debt, CSI senior notes)Covenants met, interest paidRecurring cash, low leverage (debt 4,131 against EBITA 3,077)Refuse refinancingA covenant breach at a subsidiary could trap cash (1,172 at year-end is already restricted)

Dependence runs both ways with customers: CSU needs their renewals, but each customer needs the software more than CSU needs any one customer. With sellers, the dependence runs toward CSU only in small, relationship-sourced deals; in large deals the brokers hold the power, which is why returns there are lower.

Management and incentives

Sources: 2026 management information circular (csi-mic-2026; printed pages), the 2015 and February 2021 letters, issuer announcements (csi-leadership-2026, csi-ai-2026), and market data (csu-price-history-2026-11-03). Money in USD unless marked C$.

Who decides where the cash goes: business-unit and operating-group managers propose and close most acquisitions within hurdle rates set by head office and the board (FY2025 note 23); head office (now Mark Miller as President, Jamal Baksh as CFO) allocates between groups, pursues large deals and non-VMS investments, and sets hurdles. Mark Leonard, founder and President since 1995, resigned as President on 25 September 2025, did not stand for re-election in May 2026, and stays as an adviser on "permanent engaged minority" investments (csi-leadership-2026).

Ownership and incentives

Holdings at 28 March 2026 (MIC pp.21-22); value at C$3,397.23 (3 November 2026); pay is 2025 total compensation (MIC pp.15-16).

PersonRoleCSU sharesValue (C$m)Other holdings2025 pay (USD)Stake ÷ pay
Mark MillerPresident and COO (since Sep 2025); Exec. Chair Volaris; director since 2025254,533 (1.20%)865521,237 Topicus; 806,261 Lumine1,036,219 (salary and bonus waived from 1 Jan 2026)~600x
John BillowitsChair; CSI 2003-2020 (CFO, CEO Vela)35,96112274,086 Topicus; 113,106 Lumine60,000 fees—
Jamal BakshCFO and director; at CSI since 20031,8116.24,888 Topicus; 7,033 Lumine866,296~5x
Lawrence CunninghamVice-Chair, independent1,3244.5small120,000 fees—
Robert KittelIndependent, since 20131,2034.1small100,000 fees—
Other five independent nomineesKennedy, Pastor, Parr, Schultz108-369 each<1.3 eachsmall60,000-80,000 fees—
Jeff Bender, Robin van Poelje, Damian McKayCEOs of Harris, Topicus, Vela (not directors) in the 2026 MIC; van Poelje handed the Topicus CEO role to Ramon Zanders (previously TSS Blue CEO) on 1 October 2026 and remains Topicus Chair (topicus-ceo-2026-09)not disclosed in MIC—Van Poelje must buy Topicus shares1.54m, 2.12m, 2.57m—
Mark LeonardFounder; adviser since 2026not disclosed (not a nominee)——waived salary and bonus 2023-2025—

No one owns more than 10% of the common shares (MIC p.11). The share count has been 21,191,530 since at least 2020; there are no options, restricted units or other share compensation. Directors must spend after-tax fees on shares held in escrow for an average of four years (MIC p.17).

What compounding does to these stakes. If the stock compounds at 10% a year for five years, Miller's stake gains about C$528m, roughly 500 times his last salary and bonus, which he has in any case waived. For the President, ownership dominates pay entirely. For the CFO the stake is about five years of pay, and for operating-group CEOs (holdings not disclosed) the bonus is the larger lever, so the bonus design matters most for the people who actually close deals.

The bonus design (MIC pp.12-14). Bonus = base salary × company performance factor × individual factor. The company factor rests on ROIC and net revenue growth. ROIC is "net income for bonus purposes" (excluding amortization, deferred tax, unrealized FX, bargain gains and minorities' share) divided by "Average Invested Equity Capital", a running tally of shareholders' money that adds bonus-basis income and subtracts dividends. A 5% "risk-free" rate is netted from ROIC in all but one operating group; below it, no bonus. Groups under a "keep your capital" policy treat dividends to the parent as notional loans, so capital can't be shrunk to inflate ROIC. Executives generally must buy shares with 75% of the after-tax bonus, escrowed for an average of four years (one all-cash year in five). The board did not exercise discretion for 2025. Operating-group managers are paid on their own group's ROIC, not the group's.

What the targets imply. Because amortization is excluded and capital is a running tally, ROIC here is close to cash return on all money ever invested, measured without writing it down; it can't be manufactured by amortizing old deals. The weaknesses: the 5% threshold is below any reasonable cost of equity (about 9%), and the growth term rewards size, so a manager earns more bonus from a deal at 7% than from no deal. ROIC still falls when that happens, which limits it. The weighting between the two terms is not disclosed, so the implied hurdle can't be backed out.

Track record and references

Total shareholder return. C$100 at December 2020 became C$206 by December 2025, against C$211 for the S&P/TSX Composite (MIC p.14), so the last five years matched the index after a 2024 peak of C$277. Price alone (unadjusted for the Topicus and Lumine distributions or dividends) went from C$345 (December 2014) to C$3,301 (December 2025), about 23% a year, and has since moved between C$2,196 and C$3,605 over 52 weeks (csu-price-history-2026-11-03).

Returns on capital before and after. Bonus-basis ROIC rose from 21% (2006) to 38% (2015) while average invested capital grew from 123 to 965 (csi-2015-letter, table 1). On today's evidence, which uses different definitions: return on all acquisition cost about 19% after tax (FY2025, stage 2), and the measured 2021-2025 deal yield 15.1% (stage 6). Returns on new capital have fallen by about half since the large-deal practice began in 2021, as Leonard said they would; the absolute sum deployed rose from 582 (2020) to 2,501 (twelve months to June 2026).

Decisions that failed or disappointed.

  • Altera: bought at 0.86x revenue in 2022; FCFA2S of 92 in FY2025 is 12.7% on price, but revenue is 16% below the purchase run rate and recurring revenue fell 19% in Q2 2026 (stage 3).
  • Hurdle-rate cuts: CSU's own review of 1995-2015 vintages found each cut dragged the expected IRR of all later deals down toward the new hurdle ("hurdle rates are magnetic", 2015 letter p.6). The 2021 decision to cut hurdles for large deals is the same experiment, now running.
  • 2011: when major investors put CSU up for sale, managers maximized short-term profit and cut acquisitions and initiatives (2015 letter p.7), which shows how fragile the incentive culture is to an ownership change.
  • Public-equity investments before 2015 earned high IRRs that Leonard called "largely unimportant" because they were small and short (2015 letter p.3). Asseco (580 in 2025) is the first large test of the non-VMS circle of competence; no return can be measured yet.

References. No independent references were collected (no interviews with former employees, sellers or competitors); this is a gap, recorded as zero of zero. Published evidence: Leonard's letters (candid about mistakes and incentive problems), annual meeting Q&A, and the CFO's 2021 ownership Q&A. Secondary commentary since September 2025 attributes part of the share-price fall to Leonard's departure on health grounds; that is evidence of a market reaction, not of a change in decisions.

Bench. The operating-group heads have long tenures: Miller co-founded Trapeze, CSU's first acquisition (1995), and has been with the group over 30 years; Baksh joined in 2003; Billowits (Chair) ran Vela and was CFO; Bender (Harris), McKay (Vela) and van Poelje (Topicus) run groups producing their own deal flow. Daan Dijkhuizen became Chief AI Officer on 21 October 2026 (csi-ai-2026). The succession was internal and the method is codified in the groups, which reduces key-person risk; whether head office keeps the hurdle discipline without Leonard is the open question.

Insider dealings. Insider purchases are mostly the mandatory bonus and fee purchases; SEDI filings were not reviewed, so open-market sales and their timing are unknown.

Capital allocation principles

Governing objective. Leonard's 2021 letter recasts head office as a "good steward of investors' capital" that would rather accept a lower return on a larger sum than return cash; the bonus rewards return on all invested equity plus growth. Management behaves as if long-term value per share is the goal (no issuance, no options), with a stated preference for deploying everything over distributing.

  1. Zero-based allocation: partly. Capital does move: groups with very high ROIC are told to keep and redeploy their cash, groups with poor returns send it to head office (2015 letter p.8), and head office added large-deal and non-VMS practices in 2021. But acquired businesses are almost never sold ("buy and hold forever"), so capital in a weak unit stays there.
  2. Funding strategies, not projects: mixed. Deals are approved against hurdles one by one, but within a strategy (small VMS at traditional hurdles, large VMS at lower ones, a separate non-VMS circle). Organic "initiatives" are tracked and killed if their hypotheses fail (2015 letter pp.5-6).
  3. Capital has a cost: yes. No share compensation at all, so there is no disguised financing; debt is mostly non-recourse at subsidiaries; the IRGA and Topicus/Lumine structures are explicit claims. The hurdle-magnetism finding shows management understands that a lower hurdle costs more than the marginal deal.
  4. Zero tolerance for bad growth: weak. There are almost no divestitures; the response to Altera's decline is restructuring, not exit. Shrinking businesses are kept if they produce cash, which is consistent with the IRR focus (2015 letter: the same IRR from a declining high-margin business is as good as from a grower), but it means capital is not actively recycled out of declining units.
  5. Price versus value: limited. CSU has never bought back shares, including in early 2026 at C$2,196-2,500, about 15-17x today's estimate of normalized common owner cash (C$145 a share, stage 7), and has never issued CSU shares. It paid three special dividends when it couldn't deploy cash, stopped them in 2021, and Topicus paid a special dividend in 2025. Price discipline is shown in acquisitions (walking away from auctions), not in its own stock.

Integrity and governance

Concrete evidence:

  • Leonard waived all salary and bonus from 2023 to 2025; Miller waived his from 1 January 2026 (MIC p.14). The board used no discretion on 2025 bonuses.
  • Seven of nine nominees are independent; the audit and compensation committees are independent; a majority-voting policy and an advisory vote on pay apply (MIC pp.20-30).
  • Single class of common shares, no controlling holder. CSU itself controls Topicus and Lumine with super-voting shares (50.1% of votes against about 31% and 61% economic stakes); that is an agency question for their minorities, not for CSU's holders.
  • There is no formal anti-hedging policy for officers' and directors' shares (MIC p.13), a gap given the reliance on share ownership.
  • Related parties: the IRGA with the Joday Group is the main one, set by formula and disclosed (csi-2021-ownership).

Agency costs (Mauboussin and Callahan pp.47-48):

  • Control of resources: moderate. Pay grows with size: the growth term of the bonus, plus base salaries that rise as teams manage more businesses (2015 letter p.8). The 5% threshold is low. The offsets are the ROIC term on unamortized capital and the 75% share purchase. Measured outcome: the 2021-2025 aggregate deal yield (15.1%) is well above the cost of capital, so empire-building has not yet shown up in aggregate; the large-deal returns (Altera 12.7%) are where it would.
  • Risk tolerance: mild conservatism. Heavily invested managers keep parent leverage low (no CSI facility drawn at December 2025) and hold large cash balances (3,089), which lowers returns slightly but protects against permanent loss.
  • Time horizon: well aligned. Bonus shares are escrowed for about four years; ROIC is measured on a running tally of capital, so early-year gains from under-investing are not rewarded for long.

Buybacks don't offset share compensation because there is neither. How the valuation treats agency cost: no explicit charge. The model uses zero dilution, the measured aggregate deal yield in the base, and an 8% yield (12.5x) in the downside for a world where size-driven deployment pushes returns down. Head-office pay is immaterial against owner cash (about 2,200).

Capital allocation and ownership

USD millions. Cash flow statements: FY2021 and FY2022 columns from the FY2022 report (csi-fy2022, PDF p.42), FY2023 (csi-fy2023, PDF p.41), FY2024 and FY2025 (csi-fy2025, PDF p.44). Facts are csu* in financials/facts.json; arithmetic is in valuation/calculations.json (prefixes rates, reinv, uoc, agg).

Sources and uses of cash

FY21FY22FY23FY24FY25Total
Operating cash before working capital (after cash tax)1,2551,3571,8152,2412,7389,406
Working capital45(60)(36)(45)(6)(102)
Cash from operations1,3001,2971,7792,1962,7329,304
Leases (interest and principal)(92)(105)(120)(132)(147)(596)
Capex(29)(41)(42)(67)(68)(247)
Unlevered owner cash (uoc*)1,1791,1511,6171,9972,5178,461
Interest paid on debt(40)(74)(133)(178)(196)(621)
Interest and dividends received5543356103
Acquisitions: closing cash(1,224)(1,633)(1,609)(1,347)(1,227)(7,040)
Acquisitions: holdbacks and settlements(145)(149)(238)(336)(286)(1,154)
Cash acquired with businesses153216152164173858
Financial investments, net (Asseco in FY25)2(91)94(15)(529)(539)
Common dividends(85)(85)(85)(85)(85)(425)
Minorities, preferred and Joday distributions(22)(30)—(175)(3)(230)
Net borrowing2007876577275702,941
Other financing (fees, other)(3)(10)(1)(41)15(40)
Currency on cash(16)(39)17(48)10216
Change in cash5484736961,1092,331

Cash went from 758 (December 2020) to 3,089 (December 2025), a change of 2,331; the lines sum to within rounding (4, 48, 475, 696 and 1,107 by year). Cash taxes inside operating cash were 2,010 over the window. Non-cash acquisition consideration not in the table: Topicus.com B.V. preference units (136, 2021) and WideOrbit consideration beyond the parent's cash (323, 2023).

What the table shows about priorities. Acquisitions took 7,336 net of acquired cash, 87% of the 8,461 of unlevered owner cash (92% including the non-cash consideration). Dividends took 5%, flat at USD4 a share in every year including FY2020. There were no buybacks and no share issuance. Net borrowing of 2,941, mostly non-recourse at subsidiaries plus the 2024 senior notes, roughly funded the 2,331 cash build, so CSU's own cash funded its deals and the debt mostly sits as cash (1,172 of it in subsidiaries whose distributions to the parent are restricted). The 2025 Asseco purchase (580) is the first large non-VMS use.

Investment rates per sales change

Window FY2021-FY2025: revenue rose from 3,969 (FY2020) to 11,623, a change of 7,654 (ratesSalesChange).

Rate per $1 of revenue changeFY21FY22FY23FY24FY25FY21-25
Revenue change1,1371,5161,7851,6591,5577,654
Incremental M&A (net cash; window incl. non-cash)1.071.030.950.920.861.02 (ratesMaRate)
Internally generated intangibles (R&D increase)0.14 upper bound (ratesRdRate)
Fixed capital (capex − est. PP&E depreciation)(0.004) (ratesFixedRate)
Working capital(0.04)0.040.020.030.0040.013 (ratesWcRate)

Definitions and limits:

  • M&A: closing cash plus holdbacks paid less cash acquired, plus documented non-cash consideration in the window total (7,795, ratesAcqAllIn). Including the non-cash items, FY21 is 1.19 and FY23 1.13. There were no material divestitures.
  • Intangibles: CSU capitalizes no development. R&D staff rose from 579 to 1,615 (1,036), but R&D stayed between 13.9% and 14.6% of revenue every year, so the increase mostly follows acquired revenue rather than growth spending. 0.14 is an upper bound on growth R&D.
  • Fixed capital: capex 247 against an estimated PP&E depreciation of 274 (total depreciation 809 less lease principal 535, which approximates right-of-use depreciation). Leases are excluded from this rate.
  • Working capital: the cash-flow-statement change (102 over five years). Acquired businesses bring negative working capital (deferred revenue), which is inside the purchase price.

Where CSU really invests: 99% of growth investment (7,795 of 7,870, reinvGrowthCapital) went into acquisitions. Organic growth needs no capital at all; customers prepay. The M&A rate per dollar of sales change drifted down from 1.07 to 0.86 (net cash basis) across the window because the Altera-type large deals were cheap per dollar of revenue and because acquired revenue grew after purchase. Organic growth (cumulative factor 1.18, aggOrganicFactor) explains about 714 of the 7,654 revenue increase, so acquisitions cost about 1.1x each dollar of revenue they brought.

No peer rates were computed; Roper's and Tyler's statements were not read for this stage.

Inflection points and who was in charge. Leonard was President and Baksh CFO throughout the window. The February 2021 letter lowered hurdles for large deals: Altera (May 2022, 727) and the 2022 borrowing surge (787) followed. 2023 added WideOrbit and Optimal Blue (1,209 together) and a C$213m debenture tap. 2024 replaced the drawn bank facility with 1,000 of senior notes. Deployment then stalled (1,847 → 1,683 → 1,513 from 2023 to 2025) while cash grew, and 580 went to Asseco in 2025. After Miller took over (September 2025), twelve-month deployment reached a record 2,501 to June 2026 (deploymentTtm), including DerbySoft and Synchronoss.

Reinvestment and returns

Measured, consolidated, unlevered (operating cash after tax, leases and capex, before debt interest, IRGA and minorities), which matches consolidated acquisition spending however it was financed:

FY2020FY2025ChangeCAGR
Unlevered owner cash1,0872,5171,43018.3%
FCFA2S (common, after interest, IRGA and NCI)9891,68369411.2%
FCFA2S per share (USD)46.6879.4011.2%
Revenue3,96911,6237,65424.0%
  • Reinvestment rate FY21-25: growth investment 7,870 ÷ matching unlevered owner cash 8,461 = 93% (reinvRate).
  • Lagged incremental return: the 1,430 cash increase against acquisition capital deployed 2020-2025 with the edge years half-weighted (8,156, aggMatchedCapital) = 17.5% (reinvGrossIncrementalReturn). Removing what the 2020 business would earn after its own organic growth (1,087 × 1.18 = 1,283) leaves 1,234 earned by acquisitions: 15.1% after tax, a 6.61x cash multiple (aggAchievedYield). It is a five-year rolling ROIIC, already lagged by the half-year weighting.
  • Identity check: organic growth on the base (about 3.4% a year) plus reinvestment × deal return (0.93 × 15.1% = 14.0%) gives about 17.4%, against 18.3% measured. The identity holds within a point, so the definitions are consistent.
  • Operating leverage versus capital efficiency: the EBITA margin fell from 28.4% to 26.5% and the incremental margin over the window was 25.5%. None of the growth came from operating leverage; all of it came from deploying capital at about 15%, plus a modest organic contribution.
  • The mix and each use's return: acquisitions about 99% of growth investment at 15.1%; organic growth required no net capital (working capital 102, net capex −27) and added about 196 of cash, an effectively unlimited return but a small amount; payouts were dividends (5%) and minority distributions (3%).

Where the consolidated growth went. Common owners received 694 of the 1,430 increase. The rest: the IRGA revaluation charge grew by 375 (65 → 440; 252 of FY2025's charge was the mark on the Asseco and Sygnity stakes, MD&A p.13), minorities' share by 243 (0 → 243, after the Topicus and Lumine spin-outs), and debt interest by 164, partly offset by 55 more interest received. So per-share owner cash compounded at 11%, not 18%. The model's baseline is already common-owner cash after these claims; but it means the consolidated 15.1% deal yield overstates what common shareholders keep from deals that minorities co-fund or that are debt-funded, and that the Topicus claim grows with Topicus's success.

Biases in the 15.1%. Upward: acquired businesses' post-purchase organic growth and margin maturation are counted (the model holds new cohorts flat), and the Topicus founders' ordinary units are not valued. Downward: capital is gross of the 858 of cash acquired with the businesses; if that cash were all excess the yield would be 16.8% (reinvYieldNetOfAcquiredCash). CSU itself compares operating cash with "net capital deployed".

Acquisition record

YearDeal(s)All-in priceRevenue at purchase (annual)Profit at purchaseLater evidence
2021Topicus.com B.V. (merged with TSS into Topicus) and others1,337 cash used + 136 preference unitsn/dn/dTopicus FY2025 revenue 1,746, recurring organic +7%
2022Altera (Allscripts hospitals and large practices)727846net income 0 (May-Dec 2022)FCFA2S 71 (8 months), 94 (FY23), 92 (FY25); revenue 712 in FY25
2022Other deals1,148 considerationnot material individuallyn/d—
2023WideOrbit (via Lumine)504 (273 cash, 222 special shares, holdbacks)172net income 1 (10 months)in Lumine; not separately disclosed
2023Optimal Blue705187net income 0 (3.5 months)not separately disclosed
2023Other deals1,400 considerationn/dn/d—
2024Many small and mid deals1,683 cash used (incl. holdbacks for earlier deals)n/dn/d2,069 of intangibles recognized
2025Cipal Schaubroeck (Belgian local government)258122net loss 6 (7 months)—
2025Other deals1,321 considerationnot materialn/d—
H1 2026Synchronoss (via Lumine), DerbySoft and others309 cash + 999 other considerationSynchronoss ~169Synchronoss post-close losseslumine-q2-2026-fs, csi-q2-2026
9M 2026 (final)Synchronoss 309, DerbySoft 391 (91.8%), additional deals 1,605 total consideration (1,241 cash, 313 holdbacks, 51 contingent)2,305Synchronoss 172 run rate, DerbySoft about 133 (pro forma)DerbySoft −6 and Synchronoss −2 net loss since purchase; bargain gains 17csi-q3-2026-fs pp.10–15

Aggregate FY2021-FY2025: about 7,795 of all-in net capital bought businesses that, by 2025, earned about 1,234 of unlevered owner cash (15.1% on the matched 8,156; 6.61x). Revenue acquired was roughly 6,940, so the price was about 1.1x revenue and the acquired businesses' cash margin about 18%, below the 2025 group margin of 21.7%. The large carve-outs were bought at near-zero profit, so the measured yield is mostly the result of CSU's post-purchase cost discipline, not of buying profits cheaply.

Observed deployment pace (cash used, including holdbacks): 582 (2020), 1,337, 1,782, 1,847, 1,683, 1,513 (2025), 2,501 in the twelve months to June 2026 and 2,733 in the twelve months to September 2026 (2,471 net of acquired cash; 1,861 without Synchronoss and DerbySoft). Deployment grew about 15% a year from 2021 to mid-2026 but stalled from 2023 to 2025. Net of acquired cash the 2021-2025 average is 1,461 (best 2023 +16%, worst 2021 −19%, 2020 −67%; longest quiet run two years), and since 4 November 2026 the model states a yearly deal budget anchored on that average rather than on the record twelve months (deploy* steps; register entry of that date).

Model funding and ownership bridge

The model begins with cash available to common shareholders after financing, taxes, ongoing software spending, leases and capex. It pays the USD4 annual dividend and older acquisition claims before funding new deals. Full deployment is the base and upside assumption; the downside deploys half the surplus and retains the balance. No new bank leverage finances future purchases. Annual purchases follow a stated yearly budget (base USD1,651m net in year 1; the upside starts at the September TTM, 2,471 net), deals earn half a year of cash in the purchase year, and cash the cap can't place is distributed that year rather than hoarded, following CSU's stated alternatives for FCFA2S and the 2025 Topicus special dividend.

Topicus accounting ownership is 60.65%, including the deemed future purchase of Joday's units; that is not present direct economic ownership (csi-2021-ownership, pp.2-3). The model reverses the non-cash IRGA remeasurement from annual cash and separately deducts the full 1,295 economic claim (30 September 2026), grown at an estimated 10% a year. Removing both charge and liability would create value common shareholders do not own. The 9 November review distinguishes settlement form from economic cost; signed revised terms remain unresolved. The current engine deducts this claim at exit, not as a cash payment in annual acquisition funding.

September 2026 group cash was 2,693 (debt 3,999, of which 2,527 without recourse to CSI). Minority cash, an operating reserve, the post-September closing commitments (526) and the October dividend reduce modeled deployable cash to about 1,634. 1,025 of group cash sat in subsidiaries with restricted upstream distributions, so a pooled look-through forecast doesn't prove every dollar can move. Asseco and other financial investments stay outside the acquisition budget: their dividends are removed from operating cash and their values enter terminal equity once. Bank principal is assumed refinanced; accrued interest stays charged.

Thesis and valuation

Current assessment: 9 November 2026, using the September trailing bridge and 30 September balances. The financial update was completed on 6 November. The results call is now reviewed with stated source limits; financial paths and numerical scenario weights remain unchanged.

Mission-critical vertical software earns recurring maintenance cash, while decentralized purchases add businesses across many specialist markets. Customer replacement costs support durability, but Altera and acquisition competition show that neither recurring revenue nor purchase returns are guaranteed. CSU common owners also share consolidated value with subsidiary minorities, redemption claims and creditors.

Current valuation

Saved quote CAD 3392.29, market time 2026-11-09T21:00:00.000Z; valuation date 9 November 2026 and original model exits. These are forward estimates.

HorizonBearBaseBullWeighted cash-flow IRR
5 years-1.78%13.02%22.65%13.05%
10 years0.82%12.55%18.94%11.96%

The parent now reports through September. Synchronoss, DerbySoft, other H1 purchases and July Lumine businesses add only their missing consolidation months; the late-FY25 cohort is wholly inside the new trailing window and has been removed. Other Q3 target sales and post-September commitments remain separately labeled estimates. September cash and claims already include July closings, so those payments are not deducted again. Gross consolidated sales are paired with common cash at 61.4% Lumine ownership where known; unsegmented pools retain the explicit allocation proxy.

The base’s gain from the filing roll depends mainly on normalizing the USD179m TTM working-capital outflow. The split between payment timing and acquired liabilities is undisclosed. Capping the add-back at the previous USD70m level gives about 11.45% five-year base IRR at C$3,511.69 on 6 November; this is a sensitivity, not the current quote or an observed recurring cost. Filing roll and attribution.

Pre-mortem

Synchronoss and July sales annualization are flat-quarter estimates; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks. The central estimate can fail even when a useful product or good acquisition history survives. Customer demand, supplier pricing, the capital needed for delivery and ownership/financing claims must all work together. The adverse case is a representative failure mechanism, not the largest possible loss. No new report or positive share-price move alone resolves these risks.

Exit multiple

The existing source-supported scenario capitalization and year-by-year deal budgets are retained. This bridge correction does not make more acquisition supply or justify a larger multiple. The independent debate’s finite-duration and ownership/funding attacks still constrain conviction; a claimed long runway is an estimate rather than a measured future duration. The revenue bridge does not supply independent proof of terminal value or remove the survival risks identified in the written debate. Shorter duration, poorer cash conversion and higher required returns remain relevant stresses. Historical source reproduction and current underwriting remain distinct.

Bear case

Synchronoss and July sales annualization are flat-quarter estimates; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks. The existing adverse operating and capital-allocation paths remain the coherent modeled stress. Matching sales to cash prevents a missing denominator from hiding those assumptions; it does not turn a proxy margin or assumed refinancing into a reported fact. Debt, deferred claims, operating liquidity and distributions remain funded in the same cash ledger.

Variant view

Recurring maintenance, decentralized acquisition execution and the measured purchase cash-yield proxy support the central mechanism. September TTM deployment is USD2,471m net; excluding Synchronoss and DerbySoft gives USD1,861m against the base year-1 budget of USD1,651m. That supports current executable capacity but does not measure ten years of seller availability. The explicit outside-view exception retains the modest deal budget, distributes unplaced cash and records missing target counts and win rates. Its acceptance is a judgment, not statistical proof.

At C$3,392.29 the five-year weighted estimate is 13.05%; the increase comes from a lower entry quote, not a better operating forecast. The five-year base is 13.02%, 12.29% if the working-capital add-back is capped at USD70m, and 11.81% without that add-back. These are conditional sensitivities, not reassessed scenario distributions; the apparent margin of safety depends on a normalization the call does not quantify. 9 November decision. Acquisition price, mature target margins, customer retention and the 20x base exit remain material judgments. Q3 recurring organic growth outside Altera held at 4%, while Altera recurring fell 8% and newly acquired high-attrition healthcare businesses limit any group-level reassurance. Future evidence needs to establish cash collection and acquired economics, not merely recurring-revenue labels or a larger deal budget.

The independent claim judgment and Q3 probability review remain the current risk record. Earlier investor comparisons remain in the historical reference; no new source-author forecast or market-consensus survey is inferred.

Why the opportunity exists

The following observations retain the measurement dates in their cited sources; no new holder, liquidity or short-interest survey is claimed.

Evidence (csu-price-history-2026-11-03; MIC p.11):

  • Size and liquidity. Market capitalization C$72.8bn (21.19m shares × C$3,433.89). October 2026 volume was 1.29m shares, about 59,000 a day or C$200m of daily trading value. No holder has more than 10%; directors and officers listed in the circular own about 0.3m shares, so the float is about 20.9m and turns over in roughly 360 trading days.
  • Coverage, short interest, retail ownership, index membership. Not retrieved; CSU is a large Canadian technology stock widely discussed in investor media, so neglect is unlikely to explain any mispricing.
  • What drove sellers. The price peaked near C$5,300 in May 2025. Leonard's resignation on 25 September 2025 coincided with a September close of C$3,778 (from C$4,550) on higher volume. The steepest fall came in January 2026 (close C$2,513 from C$3,301; record volume of 2.16m shares), when investor commentary attributed the selling of vertical-software stocks to fears of AI substitution (secondary sources, not verified against fund flows). Q2 2026 showed 1% organic growth and Altera's 19% recurring decline. The price has since recovered to about C$3,400-3,450.

So the discount is not neglect: it is a widely shared fear about AI and succession, partly justified by Altera and by the halving of returns on new capital since the large-deal practice began.

What would prove us wrong

Q3 2026 (6 November) was checked against this list: recurring growth outside Altera held at 4% and net deal cash rose, so neither customer erosion nor a deployment stall is yet visible (updates/2026-11-06-q3-roll.md). Still open: recurring growth outside Altera below 2% for two quarters, FY2026 net deployment below the base budget, or acquired cohorts that stay loss-making. Compare future observations with the same ownership, cost and reporting periods used in this model. Preserve earlier frozen checks and score them as their reports arrive; do not edit their forecasts to match the result. Unavailable deal disclosure needs a bounded estimate and a revision trigger, not a claim of observed target profitability.

Original revenue-bridge closure and September filing roll. The earlier initial completion audit’s three revenue gaps are now closed with reported observations and explicit estimates; the remaining limits above are ordinary underwriting uncertainty, not missing forecast outputs.

Risks and disconfirming evidence

USD millions.

Paths to permanent loss

  1. Installed-base erosion. Recurring maintenance carries about 85% of EBITA (stage 3). If AI-assisted development and data migration lower switching costs across many niches at once, renewals and price increases fall together and the decline is permanent: migrated customers don't come back. Altera (revenue −16% since purchase; recurring −19% in Q2 2026 and −8% in Q3; total organic −18% over nine months) shows what this looks like in one business. Persistent erosion outside Altera, falling retention or rising development needs would break the cash-growth assumption. Q2 MD&A, pp.5 and 16; Q3 MD&A, pp.5 and 17.
  2. Overpaying at scale. Returns on new capital have roughly halved since 2015 (38% bonus-basis ROIC then; 15.1% measured on 2021-2025 deals now). Lower hurdles for large deals are "magnetic" by CSU's own evidence (2015 letter p.6). If the bonus's growth term and the new President's mandate push deployment to auction prices, new capital can earn less than its cost while the reported deal count keeps rising. Historical corporate ROIC, a deal IRR hurdle and a cash purchase yield measure different things.
  3. Claims ahead of common. The IRGA claim (1,295 in September 2026, 741 of it classed current) grows with Topicus's value and investment marks; minorities took 243 of FY2025's pre-NCI FCFA2S and 208 in 9M 2026; 1,025 of September cash sat in subsidiaries with restricted distributions. Puts, contingent payouts and refinancing can require cash sooner than modeled. The model assumes bank refinancing and does not simulate a covenant crisis or recapitalization. Legacy acquisition tax benefits can also expire.
  4. Paying a high multiple for a slower compounder. At 23x normalized cash, a fall to the trough multiple (15x) with flat earnings would cost about a third of the price. The downside reaches −2.5% a year (C$3,511.69) only because five years of retained cash and dividends offset most of that.

Unverified inputs

Shared-engine sensitivities at C$3,392.29 on9November2026; base13.02%, fixed original exits. Each switch changes only the named assumption, without assigning new scenario probabilities.

InputCurrent modelUncertaintyIsolated five-year base sensitivity
Exit multiple20xDurability and post-exit reinvestment judgment15x: 7.07%; 25x: 17.92%
Yearly deal budgetUSD1,651m in year1, then stated pathsNo measured future seller/win-rate funnel0.75x: 11.71%; 1.25x: 14.25%
Acquired owner-cash margin15% then16.5%, reaching17.8%Mature purchase-yield proxy, not reported cohort owner cash12% throughout: 10.34%
Price per dollar of acquired revenue1.17xMatched historical net purchase price; future competition remains1.5x: 11.22%
Organic/acquired revenue growth1.5%, then2%, then3%Customer durability, product mix and eventual Altera stabilization1 point lower each year: 12.19%
Owner-cash margin on organic revenue17.48% flatCommon-owner cash on consolidated sales; mix and recurring investment estimates1 point lower: 12.03%
Normalized owner cashUSD2,309mUSD179m working-capital add-back remains unverified quantitativelyAdd-back capped70m: 12.29%; no add-back: 11.81%
Missing funded/announced contributionAbout USD243m mature cashMissing periods, purchase-yield and integration estimatesNo new reported margin inferred from the call
IRGA economic claim growth10% annuallyMixed underlying claims and unresolved revised settlement allocation15% growth: 12.89%
Deployable cashAbout USD1,634mRestricted subsidiary cash and operating-liquidity estimatesNot all consolidated cash is fungible

Disconfirming evidence to watch

Customer economics. FX-adjusted group organic growth was 2% in Q3 2026 and 1% over nine months; recurring 4% in Q3 (2% in Q2). Outside Altera recurring grew 4% in both quarters; Altera recurring fell 8% in Q3 after −19% in Q2, and management expects sizable client departures to run until the end of 2027. The US healthcare group outside Altera fell 10% in Q3, −3% without two newly bought businesses whose high attrition CSU says it priced in. Licenses fell 17% and services 5%. The steady +4% outside Altera supports the base; buying businesses that are known to shrink is a new test of the purchase yield.

AI and competition. Integration, domain rules and migration costs support incumbents, but cheaper development can lower entry barriers and change pricing expectations. The new Chief AI Officer is a response, not proof the risk is resolved. More required product spending would reduce the cash margin of existing and acquired businesses. Pricing AI substitution into acquisition screens raises the effective hurdle on AI-exposed targets, which was offered as one explanation for slower deployment alongside fewer qualifying sellers. Q3 2026 showed no group-level slowdown to explain: nine-month net deal cash was USD1,986m against 855 a year earlier (08-underwriting-plan.md, deployment test).

Deployment at scale. A larger capital base can exhaust small attractive targets, move CSU into auctions or accept lower returns. The base purchase yield is the group's measured 2020-2025 aggregate (restated net of acquired cash and at entry), earned at USD1.3-2.5bn a year of deployment; faster scaling at the same yield is the upside, not the base. Failed margin convergence, higher integration costs and idle cash reduce compounding.

Industry check, updated8 November 2026. Roper reported 7% organic growth and continuing software bolt-ons on 22 October 2026, which supports ongoing demand and acquisition competition in some specialist markets, but its mix differs from CSU's and it does not override CSU's weaker growth. Roper Q3 release. Recovered Tyler's original28 October SEC earnings exhibit, including cash and non-GAAP reconciliations. It reports11% recurring growth but also a Texas payments-contract wind-down; SaaS migration and transaction growth are different drivers. Quarterly FCF includes a large working-capital benefit and adds back share compensation in CFO. It is not CSU owner cash, a measured acquisition yield or evidence resolving CSU's working-capital normalization. No Tyler input enters the forecast. Earlier source-access limits remain in their dated records.

Coverage: issuer filings, the 2026 circular, management letters and that peer release, not every vertical or customer. No interviews or fieldwork. Investment marks are at 30 September 2026; post-September deals are a disclosed pool, not completed facts. The observations that would refute the thesis, with dates, are listed in research/05-thesis.md under "What would prove us wrong".

Surviving debate attacks — 5 November 2026

Low to moderate; recurring product economics supported, current ownership/funding and full revenue bridge incomplete. Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.

Discriminating evidence named then (Q3 2026) has arrived; see 12-debate.md for the outcome. The complete debate sizes these risks using the shared forecast; a sensitivity is neither a measured fact nor a calibrated probability.

Revenue bridge closure and remaining uncertainty — 5 November 2026

The previously missing sales/cash perimeter is now modeled. Synchronoss and July sales annualization are flat-quarter estimates; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks. Q3 2026 has since replaced the June bridge (6 November; 07-assumption-register.md). This closes the missing forecast output rather than claiming that the target economics or refinancing outcomes are certain. Earlier source-gap statements in the dated debate describe its initial information set; current inputs are in 07-assumption-register.md.

Current assumption register

Evidence assessment: 9 November 2026; financial bridge: 6 November Q3 roll. Reported facts, issuer pro-forma estimates, normalization and forward judgments remain separately classified.

The 9 November call review retains the quantitative bridge and weights. IRGA is an economic exit claim, not assumed all-cash funding; working-capital neutrality remains an unverified normalization. Source limits and fixed-price impact checks are recorded there.

Reported starting bridge

The bridge now starts from the twelve months to 30 September 2026 (FY2025 + 9M 2026 − 9M 2025) and 30 September balances. Reported TTM FCFA2S is USD1,946m; adding back the USD309m noncash IRGA charge, neutralizing the USD179m working-capital outflow, and normalizing interest and investment income gives USD2,309m of common-owner operating cash (June: 2,197). Missing-month windows shrink: Synchronoss, DerbySoft and the July Lumine businesses now have owned Q3 sales in the base; other H1 deals lose half their gap, and the late-FY25 cohort is removed because it now lies wholly inside the TTM. Gross consolidated sales are paired with common cash at the specific 61.4% Lumine ownership where known and the allocation estimate only for unsegmented pools. The largest judgment in the roll is the working-capital add-back: capping the add-back at the June TTM outflow (70) would lower the five-year base by about 0.7 points.

InputValueClassificationDefinition/evidence
equityCashEarnings3237.859underwriting estimateReported TTM FCFA2S plus the noncash IRGA revaluation; normalize working capital, remove cash/investment income, charge accrued economic debt cost and adjust the identified transaction cost. The full IRGA stock is separately valued at exit. Reported cash already excludes NCI; the allocation fraction is applied only to otherwise unallocated adjustments.
shares21.192reported21,191,530 basic and diluted common shares at 30 September and 6 November 2026, unchanged from December. No second preferred or super-voting economic class is added.
openingCash2292.339underwriting estimate30 September cash less external minority cash, a maximum Adapt minority reserve, the post-September closing commitments, the October dividend and ten days of operating liquidity. This is a look-through funding estimate; cash inside subsidiaries is not freely transferable to parent.
revenue18518.610reportedTrailing twelve months to 30 September 2026 consolidated revenue (FY2025 + 9M 2026 − 9M 2025 = USD13,204m) in CAD at 1.4025; calculation revenueTtmCad.

Known and committed cohort bridge

Revenue is consolidated gross; cash is on the model’s common-owner or cash-NOPAT perimeter. A reported sales observation is not a reported cash margin. Missing months exclude sales already in the starting baseline. Capital already paid or reserved is not purchased again.

CohortMissing annual salesMissing/mature cashTiming and basis
Synchronoss missing owned contribution91.30611.818Latest complete owned quarter (Q3, 43.1) times four, less the 107.4 already in the September TTM. Cash still ramps because applying a group margin is an integration estimate.
DerbySoft missing contribution121.08225.524Nine-month pro-forma sales (53 missing before 1 June plus 47 owned) annualized flat, less the 47 already in the September TTM. Seasonality and profit normalization remain estimates, so both sales and cash ramp.
Other H1 funded acquisitions, missing months542.87886.103Matched net capital/revenue price; an average April closing leaves half a year missing from the September TTM (was 75% of a year against June). Sales and cash are explicit pooled estimates, not new reported facts.
Quortex and Imagine: completed July acquisitions240.34140.858Q3 is the first full owned quarter; it is already in the September TTM, so only three quarters are added. Current purchase cash/deferred claims replace old estimates; mature cash margin ramps separately. No new purchase or facility draw.
Post-September completed/open commitments746.168118.345Post-September completed/open pool only. Paid closing amounts are reserved from September cash; deferred claims reserved separately. Mixed closing status requires a timing ramp.
Other Q3 acquisitions, provisional missing months362.79057.540Q3 additional acquisitions: 9M additional consideration (1,605) less the H1 cohort (999) and the separately modeled July Lumine businesses (231.5) = 374.5, which includes measurement-period revisions. Sales use the matched gross capital/sales price; an average mid-quarter close leaves 10.5 months missing. Provisional estimate, not a reported cohort.

Forward scenario mechanisms

Mission-critical vertical software earns recurring maintenance cash, while decentralized purchases add businesses across many specialist markets. Customer replacement costs support durability, but Altera and acquisition competition show that neither recurring revenue nor purchase returns are guaranteed. CSU common owners also share consolidated value with subsidiary minorities, redemption claims and creditors.

The existing source-supported scenario capitalization and year-by-year deal budgets are retained after the Q3 test: nine-month net deal cash (USD1,986m) already exceeds the base full-year budget, so the base is not too high on current evidence. The budget waits for FY2026 to enter the full-year average. The upside year 1 follows its binding to the September TTM (USD2,471m). This roll does not make more acquisition supply or justify a larger multiple. The independent debate’s finite-duration and ownership/funding attacks still constrain conviction; a claimed long runway is an estimate rather than a measured future duration.

base

Latest group organic growth is 1% after FX. Continue current ongoing spending and flat dividends; deploy surplus into cash-funded acquisitions at the group's achieved 2020–2025 aggregate acquisition cash yield. Exit at a chosen 20x operating equity cash multiple, with investments and all retained claims added/deducted separately.

DriverValue/pathReason and sources
exitMultiple20.000Chosen terminal operating equity cash yields are 5%, 6.67% and 4%, giving 20x, 15x and 25x. They reflect alternative cash durability and reinvestment runway; they are independent judgments, not historical deal returns or current-price-reset formulas. Retained assets and IRGA/other claims are valued separately.
dilutionRate0.000Zero further issuance follows the unchanged reported share count. Future DRIP, compensation or financing issuance would require a revision; no speculative buyback gains are included.
reinvestmentRate1.000Base/upside full deployment follows the stated acquisition objective after dividends, operating reserve and old claims. The 50% stress retains cash if qualifying opportunities are scarce. Full deployment is not proof that the same purchase yield remains available at scale.
organicGrowth, years 1–10.015Year 1 (Nov 2026-Oct 2027): revenue-weighted mix of the latest FX-adjusted organic rates (Q3 2026). CSU excluding Altera (96% of nine-month revenue) grew 3% in Q3 and 2% over nine months, with recurring revenue +4% in both; Altera (445 of 10,027, 4%) fell 17% in Q3 and 18% over nine months (recurring −8% and −11%; licenses −52%, services −30%). Mix: about 2.4 points from the rest less about 0.8 from Altera, roughly 1.6%. Group FX-adjusted organic growth over the last four quarters ran 2%, 1%, 1%, 2%. Q3 confirms 1.5%; no change. Sources: csi-q2-2026, csi-fy2025, csi-q3-2026-fs, csi-q3-2026-mda
organicGrowth, years 2–30.020Years 2-3: Altera laps its upfront-contract comparison and declines about 5% a year (its FY2025 recurring was −3%); licenses and services shrink about 2% as their 2024-2025 declines slow. Recurring outside Altera stays at +4%. Mix gives about 2%. Q3 2026 check: management expects the sizable Altera client departures to run their course by the end of 2027 (inside year 2), so Altera may fall faster than 5% in year 2; at 4% of revenue a 10% fall would cost only about 0.2 points. Kept at 2%. Sources: csi-q2-2026, csi-fy2025, csi-q3-2026-mda
organicGrowth, years 4–50.030Years 4-5: Altera stabilizes and licenses/services stop shrinking, so group organic growth returns to the recurring-led rate seen in FY2025 (3% FX-adjusted) and the 2021-2025 average (3.4% reported, about 3% FX-adjusted). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicGrowth, years 6–100.030Years 6-10: the long-run rate of an installed base that renews and takes modest price increases: FY2025 3% FX-adjusted, 2021-2025 average about 3%. No AI disruption and no AI-driven acceleration is assumed; both are scenario questions. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicMargin, years 1–100.175Flat at the starting owner-cash margin (17.48%), justified for all ten years: (1) the mix shift nets to about zero, because shrinking licenses carry a 63% EBITA margin and shrinking services 6%, while growing recurring revenue carries 30% (stage 3 unit economics; year-1 EBITA +1.7% against revenue +1.5%); (2) R&D has stayed at 13.9-14.6% of revenue every year 2020-2025; (3) Topicus grows faster with about 40% leaking to minorities and the IRGA, a drift of only about −0.02 points a year; (4) no AI productivity gain is evidenced yet. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
priceToSales, years 1–101.169Measured price per dollar of acquired revenue, 1.17x (net capital at entry, 2021-2025 cohorts). Flat because the evidence shows no rising trend: acquisition capital per dollar of sales change fell from 1.07 (FY2021) to 0.86 (FY2025) while deal size grew, and the aggregate already includes the large deals (Altera 0.86x, Synchronoss 1.8x, Cipal Schaubroeck 2.1x, WideOrbit 2.9x, Optimal Blue 3.8x). Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 1–10.150Year 1: only newly bought businesses contribute (half a year), and new cohorts start below the blended 17.8%: Altera earned 12.8% FCFA2S on revenue in its first eight months (71 / 556), Cipal Schaubroeck and Synchronoss reported post-close losses. 15% is the midpoint between Altera's first-year level and the blended aggregate. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 2–30.165Years 2-3: the model's acquired pool is still young (average age about 1-1.5 years against 2.3 years for the measured 2021-2025 pool), so margins are between first-year levels (Altera 12.8%, 11.6% in its first full year) and the blended 17.8%. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 4–100.178Years 4-10: the pool reaches the age mix of the measured 2021-2025 cohorts (about 2.3 years), so it earns their measured entry-basis margin, 17.8% (acquiredMarginMeasured). Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredGrowth, years 1–10.015Year 1: acquired businesses grow like the group (CSU's organic measure includes them from purchase), with the same Altera and license drag. Sources: csi-q2-2026, csi-fy2025
acquiredGrowth, years 2–30.020Years 2-3: as organic growth; recent large carve-outs (Altera, Synchronoss) shrink while small VMS deals grow like the base. Sources: csi-q2-2026, csi-fy2025
acquiredGrowth, years 4–100.030Years 4-10: the group long-run organic rate, about 3% FX-adjusted 2021-2025, which includes acquired businesses after purchase. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
deploymentCapacity, years 1–12315.112Year 1: the expected budget, with no lump placed (no deal beyond the reserved post-September pool has an evidenced date): the 2021-2025 through-cycle net average (USD1,461m) moved to 2027 at the measured ~3% trend = USD1,651m. Q3 2026 test: nine-month net deal cash was USD1,986m (1.20 times this full-year budget), Q3 alone 550 against 307 a year earlier; the twelve months to September excluding Synchronoss and DerbySoft were USD1,861m (1.13 times). Group deployment did not slow in 2026, so neither fewer sellers nor a higher AI hurdle is visible in the aggregate. Kept: the stage rule uses full-year through-cycle averages, not a peak, and a partial year with two large deals is not a full year. Revision trigger: when FY2026 is reported, the 2022-2026 window replaces 2021-2025; at about USD2.5bn net for 2026 the average would rise about 18%. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital, csi-q3-2026-fs, csi-q3-2026-mda
deploymentCapacity, years 2–22384.600Year 2: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,700m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 3–32456.100Year 3: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,751m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 4–42529.800Year 4: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,804m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 5–52605.700Year 5: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,858m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 6–62683.800Year 6: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,914m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 7–72764.400Year 7: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD1,971m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 8–82847.300Year 8: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD2,030m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 9–92932.700Year 9: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD2,091m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 10–103020.700Year 10: the expected budget, the year-1 anchor grown at the measured ~3% trend (USD2,154m net). The 2021-2025 average already contains the record's weak years (2021 at −19%), and no deal with an evidenced date falls in this year, so no dip or lump is placed. The ~3% is the measured growth in qualifying deal supply: net deployment rose 3% a year from 2021 to 2025 while owner cash more than doubled (deployNetToOwnerCash* fell from 100% to 53%). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital

downside

Stress 2% annual erosion of the existing cash base, deploy only half the available surplus, earn an 8% mature purchase cash yield and exit at 15x. This tests weaker retention, Altera pressure, poorer deal economics and a shorter runway; retained cash remains an asset. It is not a default scenario.

DriverValue/pathReason and sources
exitMultiple15.000Chosen terminal operating equity cash yields are 5%, 6.67% and 4%, giving 20x, 15x and 25x. They reflect alternative cash durability and reinvestment runway; they are independent judgments, not historical deal returns or current-price-reset formulas. Retained assets and IRGA/other claims are valued separately.
dilutionRate0.000Zero further issuance follows the unchanged reported share count. Future DRIP, compensation or financing issuance would require a revision; no speculative buyback gains are included.
reinvestmentRate0.500Base/upside full deployment follows the stated acquisition objective after dividends, operating reserve and old claims. The 50% stress retains cash if qualifying opportunities are scarce. Full deployment is not proof that the same purchase yield remains available at scale.
organicGrowth, years 1–10.000Year 1: AI-assisted substitutes and budget pressure stall renewals: recurring growth outside Altera falls from 4% to about 1%, Altera keeps falling 15%, licenses and services −5%. Net about 0%. Sources: csi-q2-2026, csi-fy2025
organicGrowth, years 2–10-0.020Years 2-10: migrations under way; recurring revenue declines about 1-2% a year as customers leave and price increases stop, licenses and services keep shrinking. Explicit erosion stress. Sources: csi-q2-2026, csi-fy2025
organicMargin, years 1–10.175Year 1: starting margin; costs have not yet been cut. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicMargin, years 2–50.165Years 2-5: operating deleverage. R&D (13.9% of revenue) is held in absolute terms to defend products while revenue falls 2% a year, cutting the margin about 0.2-0.3 points a year. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicMargin, years 6–100.155Years 6-10: further deleverage and price pressure; margin settles about 2 points below today, still above Altera's 12.9%. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
priceToSales, years 1–101.500Auction pricing: private capital and CSU's own scale push the price per dollar of revenue to 1.5x, between the measured 1.17x and Synchronoss's 1.8x. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 1–100.120Acquired businesses reach only Altera-like margins (12.9% FCFA2S margin in FY2025), so the deal yield is 12% / 1.5 = 8%, the same 8% stress as before the rebuild. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredGrowth, years 1–10-0.020Acquired businesses erode like the rest of the portfolio. Sources: csi-q2-2026, csi-fy2025
deploymentCapacity, years 1–11879.350Year 1: the latest full year, FY2025 net USD1,340m (8% below the five-year average), as the 2023-2025 decline continues. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 2–3680.200Years 2-3: a two-year dry spell at the 2020 level (USD485m net, 33% of the average), at least as long as the record's longest quiet run (2020-2021, both below 90% of the average): sellers wait out lower valuations or private capital outbids CSU. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 4–101879.400Years 4-10: back to the FY2025 level with no growth, as in 2022-2025 when deployment was flat to falling. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital

upside

Use 3% existing cash growth, full cash deployment, the achieved 15.1% aggregate purchase cash yield (no better-than-record deal prices) and a 25x exit. Requires resilient customer economics and continued sourcing discipline. No margin expansion, new leverage or rerating of retained investments is credited.

DriverValue/pathReason and sources
exitMultiple25.000Chosen terminal operating equity cash yields are 5%, 6.67% and 4%, giving 20x, 15x and 25x. They reflect alternative cash durability and reinvestment runway; they are independent judgments, not historical deal returns or current-price-reset formulas. Retained assets and IRGA/other claims are valued separately.
dilutionRate0.000Zero further issuance follows the unchanged reported share count. Future DRIP, compensation or financing issuance would require a revision; no speculative buyback gains are included.
reinvestmentRate1.000Base/upside full deployment follows the stated acquisition objective after dividends, operating reserve and old claims. The 50% stress retains cash if qualifying opportunities are scarce. Full deployment is not proof that the same purchase yield remains available at scale.
organicGrowth, years 1–10.025Year 1: recurring growth outside Altera returns to 5% (FY2025 FX-adjusted recurring), Altera stabilizes at −5%. Sources: csi-q2-2026, csi-fy2025
organicGrowth, years 2–100.040Years 2-10: recurring at its 2024-2025 range (4-6% FX-adjusted by quarter) and licenses and services flat; reported organic growth was 4% in FY2025. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicMargin, years 1–30.175Years 1-3: starting margin; mix shift nets to about zero. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
organicMargin, years 4–100.180Years 4-10: AI tooling lowers development, support and services cost (staff in those three functions is about 35% of revenue); a 2% efficiency adds about 0.6-0.7 points of margin. Not evidenced yet, hence upside only, and only after year 3. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-ai-2026
priceToSales, years 1–101.169Measured price per dollar of acquired revenue, 1.17x (net capital at entry, 2021-2025 cohorts). Flat because the evidence shows no rising trend: acquisition capital per dollar of sales change fell from 1.07 (FY2021) to 0.86 (FY2025) while deal size grew, and the aggregate already includes the large deals (Altera 0.86x, Synchronoss 1.8x, Cipal Schaubroeck 2.1x, WideOrbit 2.9x, Optimal Blue 3.8x). Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 1–10.160Year 1: new cohorts start below the blended margin, as in the base, but integrate faster. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredMargin, years 2–100.178Years 2-10: measured blended acquired margin, 17.8%. Sources: csi-fy2022, csi-fy2023, csi-fy2025, lumine-q2-2026-fs, csi-q2-2026
acquiredGrowth, years 1–10.025Year 1: recurring growth outside Altera returns to 5% (FY2025 FX-adjusted recurring), Altera stabilizes at −5%. Sources: csi-q2-2026, csi-fy2025
acquiredGrowth, years 2–100.040Years 2-10: recurring at its 2024-2025 range (4-6% FX-adjusted by quarter) and licenses and services flat; reported organic growth was 4% in FY2025. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025
deploymentCapacity, years 1–13465.578Year 1: the record twelve months to September 2026 continue (USD2,471m net, bound to the observed TTM; USD2,308m at June): the new President's first year set a record and the large-deal practice keeps closing deals like Synchronoss and DerbySoft. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital, csi-q3-2026-fs, csi-q3-2026-mda
deploymentCapacity, years 2–33716.600Years 2-3: USD2,650m average, about 7% a year above the September record (set when the June record was USD2,308m; not rebased, since a higher TTM does not show more sellers), below the 15% a year from 2021 to mid-2026, as more operating groups and the large-deal team source in parallel. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 4–54516.100Years 4-5: continued ~10% growth (USD3,220m average). Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital
deploymentCapacity, years 6–106367.400Years 6-10: continued ~10% growth (USD4,540m average); needs sourcing to scale with cash, which 2022-2025 did not show. Sources: csi-fy2021-mda, csi-fy2022, csi-fy2023, csi-fy2025, csi-q2-2026, csi-2021-capital

Estimation limits and revision triggers

Synchronoss and July sales annualization are flat-quarter estimates; the Q3 additional-acquisition cohort (USD374.5m of consideration) is a residual that includes purchase-accounting revisions; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks.

Next triggers: the 9 November Q3 call (deal-flow and AI-hurdle commentary, treated as management claims); FY2026 results (full-year net deployment re-bases the deal budget; Q4 working capital tests whether the 9M outflow reverses); Altera recurring growth through the end-2027 client departures.

Named arithmetic, stable fact IDs and source links are retained in valuation/calculations.json. Inputs follow the filing; the IRR effect was computed afterwards and no input was tuned to it.

Q3 2026 roll, 6 November 2026

The Q3 statements and MD&A were read from the primary PDFs and the September bridge replaces the June one. Before/after inputs and returns at the same quote and date are in the dated update and its model-change record.

Underwriting plan

Written on 3 November 2026 for the model anchored 27 October 2026; rolled to the Q3 2026 filing on 6 November 2026 (exits unchanged). Money in USD millions unless marked CAD; the model runs in CAD at 1.4025.

Opportunity ledger

OpportunityStarting pointCustomer need and why CSU winsReachable in five yearsInvestment and cash costTiming and limitsEvidence against
Installed-base price and retention (recurring)8,700 recurring revenue (FY2025), 75% of revenue, about 85% of EBITAMission-critical workflow software with costly migration; CSU maintains it (R&D 13.9% of revenue)+3% to +5% a year if 2024-2025 FX-adjusted recurring growth (4-6% by quarter) holds; roughly flat if Q2 2026 (+2%) persists. Q3 2026: +4% group, +4% outside Altera, +5% outside US healthcare and AlteraAlready in the cost base: R&D, maintenance staff. No capitalAnnual renewals; public-sector budget cyclesAltera recurring −19% in Q2 2026, −8% in Q3; AI-assisted replacement could raise churn and cap price increases
New licenses, implementation, hardware2,923 (FY2025), declining (licenses −8%, services −4% FX-adjusted)New modules and new customersFlat to decliningServices staff 1,202Cyclical; Covid showed licenses −28% in one quarterLow margin; matters little to cash (stage 3)
Altera stabilization712 revenue, FCFA2S 92 (FY2025); 445 and 72 in 9M 2026, 4% of group revenueHospital EHR and practice softwareRange: further 10-20% revenue decline to stabilizationRestructuring cost already expensedHospital IT replacement cycles of several yearsRevenue down 16% since purchase; 9M 2026 total organic −18% (recurring −11%); management expects sizable client departures to continue to the end of 2027
Small and mid VMS acquisitions at traditional hurdlesMost of the 2,733 deployed in the year to September 2026 (2,471 net of acquired cash; 1,861 net excluding Synchronoss and DerbySoft)Founders who want a permanent owner; proprietary pipeline across six operating groupsBase budget USD1,651m net in year 1 growing about 3% (2021-2025 average 1,461; record TTM 2,471 not used as the anchor)Purchase price about 6.6x entry owner cash (16.4% measured net, 15.2% at entry); acquired working capital negativeLimited by sourcing and by managers' capacity to integrate; no new leveragePE competition when rates fall; two recent US healthcare purchases carry very high known attrition (healthcare recurring −10% in Q3, −3% without them); acquired cohorts earned 18% cash margins against 21.7% for the group
Large VMS businesses and carve-outs (lower hurdle)Altera 727, Optimal Blue 705, WideOrbit 504, Synchronoss 309, DerbySoft 391 (91.8%, June 2026)Corporate sellers want speed; CSU now bids in auctionsLumpy: 0-2 deals a year (40-70 large VMS businesses are sold annually)Lower yields: Altera 12.7% levered; DerbySoft cost about 2.5x net closing cash per dollar of annualized sales, twice the 1.17x the base paysBrokers invite CSU into a minority of processesShrinking revenue at the large carve-outs
Non-VMS investments (Asseco, PEMS)Asseco group fair value 1,092 (September 2026); Sabre 13%Leonard's new circle of competenceNot forecastCarried at fair value, outside deploymentLeonard now an adviser for thisNo measurable record
AI-driven internal productivityR&D, maintenance and services staff cost about 4,040Cheaper development and supportUpside only, from year 4: +0.6 points of owner-cash margin (a 2% saving on that cost base); base and downside hold the margin flat because savings are first spent defending the installed baseChief AI Officer appointed October 2026 (csi-ai-2026)No margin gain in years 1-3 in any caseSavings may be competed away through lower prices or reinvested in product without lifting margin

Overlap: acquired cohorts' later organic growth is not in the organic rate (the engine holds new cohorts flat), and the deal yield is the measured aggregate that includes such growth, so each effect appears once. Organic cash growth applies only to the existing portfolio and previously funded cohorts.

Absolute scale check (base, five years). Revenue rises from USD13,204m (trailing to September 2026) to USD23,245m in year 5, including committed and missing-month cohorts. Owner cash rises from CAD3,238m to CAD5,702m, 1.8x. Five-year deployment is CAD12,291m (USD8,764m net), about 1.2x the 7,304 of net acquisition cash in 2021-2025, matching the record's roughly 3% annual growth in deal supply; about CAD11,277m beyond regular dividends is distributed because the budget, not cash, binds (as in 2025, when CSU deployed 53% of its unlevered owner cash). At the measured price of about 1.1-1.4x revenue, that buys roughly 10,000-13,000 of revenue, close to doubling the group, which would need roughly as many additional employees as CSU has today and twice the recent number of deals or larger deals. That is the base case's largest demand on the organization. The downside deploys CAD6,999m at 1.5x revenue (with a two-year drought) and the upside CAD19,931m.

Management targets as bounds. CSU publishes no growth or margin targets. The stated intent (2021 letter) is to deploy all FCFA2S rather than distribute it; the bonus rewards ROIC above 5% and revenue growth. The base states a yearly deal budget anchored on the 2021-2025 through-cycle average (about 3% growth, no placed dips) rather than assuming all cash is placed, and prices deals at the measured aggregate rather than at any hurdle. Following the overprecision lesson, the scenario range is wider than any historical pattern: the downside has deployment and returns well below anything in 2021-2025.

Scenario mechanisms

DownsideBaseUpside
Organic revenue growth (years)0% (1), −2% (2-10)1.5% (1), 2% (2-3), 3% (4-10)2.5% (1), 4% (2-10)
Owner-cash margin on organic revenue17.5% (1), 16.5% (2-5), 15.5% (6-10)17.48% flat17.5% (1-3), 18.0% (4-10)
Acquired businesses' margin12%15% (1), 16.5% (2-3), 17.8% (4-10)16% (1), 17.8% (2-10)
Acquired revenue growth−2%as organicas organic
Deal cash in the purchase yearhalfhalfhalf
Price per dollar of acquired revenue1.5x (8% yield at 12% margin)1.17x (15.2% yield once mature)1.17x
Share of surplus cash offered to deals50%100%100%
Yearly deal budget (USD m net)1,340; 485 dry spell (y2-3); 1,340 (y4-10)1,651 growing about 3% a year to 2,154 (y10); no placed dips2,471 (September TTM); 2,650 (y2-3); 3,220 (y4-5); 4,540 (y6-10)
Unplaced cashretained (half the surplus) and paid if the cap bindsdistributed in the yeardistributed in the year
Financing and dilutionno new debt, no sharessamesame
IRGA claim1,295 (September 2026) growing 10% a yearsamesame
Exit multiple of operating equity cash15x20x25x
Year-5 revenue (USD m)16,48823,24528,652
Year-5 cash earnings (CAD m)3,6315,7027,161

Mechanisms behind each assumption:

  • Downside. AI-enabled competitors and customers' budget pressure erode the installed base: renewal pricing stalls and churn rises enough that existing cash declines 2% a year (recurring revenue falling about 1-2% after cost cuts). At the same time private capital bids up VMS prices or CSU accepts lower returns at scale, so new deals earn 8%. Fewer deals clear the hurdle, so half the surplus stays in cash. The 15x exit follows from slower growth and lower returns on new capital (Koller: at 9% cost of equity, 4% growth and 15% RONIC give about 15x), not from the lower earnings themselves. This is a lasting impairment of part of the franchise, not a temporary under-use: the software doesn't come back once customers migrate.
  • Base. The installed base grows about 3% a year: recurring revenue (about 85% of EBITA) grows 4-5% outside Altera while licenses, services and Altera shrink, which weights to about 3% of profit, the same as the 2021-2025 average organic rate (3.4%). Acquired businesses grow at the same rate, because CSU's organic measure already includes them; their purchase yield is stated at entry so that growth is not counted twice. Deals continue at the measured 2021-2025 yield within a yearly budget anchored on the 2021-2025 through-cycle average (USD1,461m net), moved to 2027 at the measured ~3% trend and growing at that trend. No dips are placed: the average already contains the record's weak years, and a lump goes in a specific year only when its timing is evidenced by an announced, signed or financed deal (none beyond the reserved post-September pool of USD673m). The downside's dry spell is a scenario mechanism, not a timing forecast. Each deal is funded from cash before it contributes and earns half a year of cash in its purchase year, the same convention used to measure the yield. The 20x exit corresponds to about 6% perpetual growth at 15.2% RONIC and a 9% cost of equity.
  • Upside. Recurring growth returns to the 2024-2025 range (5% cash growth) and sourcing scales with cash (the record pace continues and grows about 10% a year) at the same measured yield, with no better prices than the record. The 25x exit needs its own mechanism: a longer runway at 15% RONIC (about 6.8% perpetual growth gives 25x). It is not granted by higher growth alone.

Temporary versus permanent. A deployment stall (2023-2025) is temporary under-use: cash accumulates and the model distributes or retains it at par. Customer migration away from a product is permanent and is what the downside's −2% represents. Integration takes time: a new cohort earns half a year in its purchase year and its entry run rate from the next year; previously funded cohorts valued on mature estimates ramp over one year. The model uses the shared equity-acquirer adapter (after-financing common cash with funded acquisition cohorts, deployment capacity, retained claims and assets); input notes in valuation/model.json record each input's classification and sources.

Q3 2026 deployment test — 6 November 2026

Question: did 2026 deployment slow, and if so, because fewer qualifying sellers came to market or because CSU raised its hurdle on AI-exposed targets (updates/2026-11-06-topicus-ai-briefing.md)?

The premise fails at group level. Net deal cash was USD1,986m in the first nine months of 2026 against 855 a year earlier; Q3 alone was 550 against 307. Nine months already exceed the base full-year budget (1.20x), and the twelve months to September (2,471) are a record. Without the two named large deals (Synchronoss 275 and DerbySoft 335 net) small and mid-sized deals still absorbed 1,861, 1.13x the base year-1 budget. The decline that is real is deployment as a share of cash, 2021-2025.

What each explanation predicts, and what Q3 shows:

TestFewer qualifying sellersHigher hurdle on AI-exposed targetsQ3 2026 evidence
Deal cashFallsFalls, or shifts to less-exposed verticalsRose: 9M net 1,986 vs 855
Price per dollar of salesRises (more bidders per seller)Falls on exposed targetsNot measurable for small deals (no target sales disclosed); DerbySoft about 2.5x net closing cash per dollar of sales, high
Verticals boughtUnchangedFewer content and knowledge-work nichesStill bought content management, marketing, legal, education and accounting software
Declining targetsAvoidedBought only at prices that model the declineTwo US healthcare purchases with very high, known attrition were "modeled as part of the respective investment theses" (MD&A p.5)
Bargain gainsNo changeMore17 vs 6 (9M), small

Verdict: neither explanation is visible in the aggregate, because deployment did not slow. The healthcare purchases fit a hurdle that prices decline rather than one that avoids it. The filings cannot separate the two explanations at the level of individual deals: no deal count, no target sales and no rejected-deal data are disclosed. No deployment path changes. The base stays at the full-year through-cycle average and moves when FY2026 enters that average. Next evidence: the 9 November call (management claims, not data), Topicus's own deal pace, and FY2026 net deployment by segment.

Revenue bridge — rolled to September 2026

The 5 November closure built the cohort bridge on the June parent window. Q3 now replaces it: Synchronoss, DerbySoft and the July Lumine businesses have owned Q3 sales inside the September TTM, so only their missing quarters remain. Other H1 deals keep half a year, the late-FY25 cohort is removed (wholly inside the TTM), and a provisional Q3 cohort (USD374.5m consideration) is added. The post-September pool (526 closing, 148 deferred) replaces the post-June pool. Base revenue is CAD32,601m in year 5 and CAD50,002m in year 10; operating owner cash is CAD5,702m and CAD8,787m. Sales annualizations are flat-quarter estimates and mature target cash margins are not reported owner cash. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks.

Inputs before and after, and returns at the same quote and date. The 5 November closure record stays in updates/2026-11-05-revenue-bridge-closure.json.

Capital productivity and reinvestment

Assessment:5November2026. These are shared-engine diagnostics from the same owner-cash projection shown in the dashboard, not a new historical measurement. Money is in CAD millions.

HorizonScenarioReturn/proxy definitionRatePeriod-weighted reinvestmentNew growth capitalMatching earningsFunding residual
5 yearsdownsideAcquisition ROIIC · mature cash proxy8.00%40.69%6998.55017200.9635.46e-12
5 yearsbaseAcquisition ROIIC · mature cash proxy14.33%54.35%12291.31222614.3341.82e-12
5 yearsupsideAcquisition ROIIC · mature cash proxy14.96%74.85%19607.28726193.8283.64e-12
10 yearsdownsideAcquisition ROIIC · mature cash proxy8.00%46.21%16395.55035477.8263.64e-12
10 yearsbaseAcquisition ROIIC · mature cash proxy14.81%44.75%26540.21259312.2043.64e-12
10 yearsupsideAcquisition ROIIC · mature cash proxy15.12%64.68%51444.28779539.7727.28e-12

The June parent reporting window remains unchanged. The bridge now separates Synchronoss, DerbySoft, other H1 purchases, late-FY25 purchases, completed July Lumine businesses and other completed/open commitments. Latest Lumine Q3 owned sales update the forward missing-period estimates; the parent has not yet reported Q3. Gross consolidated sales are paired with common cash at specific 61.4% Lumine ownership where known, using the existing allocation estimate only for unsegmented pools. The same ownership now applies to known July cash/deferred reservations.

Reinvestment is total new growth investment divided by total matching earnings, not an average of annual percentages. Previously funded cohort contributions are not new investment returns. Acquisition cash-yield proxies and forecast-implied productivity are not measured historical ROIIC or project IRRs. All dividends, existing claims, liquidity and financing are reconciled before new purchase capital.

Synchronoss and July sales annualization are flat-quarter estimates; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks.

Historical measurements and definitions remain in 04-capital-allocation.md and valuation/calculations.json. Dated source bridge and funding ledger.

Scenario probabilities

Assessment date: 2026-10-27; last reassessed 2026-11-06. These are initial subjective judgments, with low confidence. Financial sources support the mechanisms, not measured numerical odds. The original authors did not provide or endorse these weights.

HorizonDownsideBaseUpside
5 years20%60%20%
10 years30%50%20%

5-year reasoning: A diverse installed base and demonstrated acquisition process support the central cash-generation mechanism. The forecast still depends on normalized common-owner cash, restricted subsidiary funding and sustainable purchase returns.

10-year reasoning: The growing absolute acquisition budget and accumulated ownership/refinancing claims make full deployment less certain over a decade. Shift weight from central to downside instead of assuming historical deal returns persist indefinitely.

Downside: Retention, Altera performance or higher purchase prices can impair cash while slower deployment preserves liquidity. Financing, IRGA and subsidiary claims justify a material downside weight despite diversification.

Base: Low organic growth, recurring customer cash and disciplined purchases are consistent with the observed model. Full deployment at the inferred yield remains a judgment rather than an observed forward pipeline.

Upside: Stronger existing cash growth and continued attractive sourcing can outperform. The larger transaction scale and assumed 25x exit prevent treating the favorable path as equally established as base.

Review triggers:

  • Organic cash growth and customer retention.
  • Acquisition spend, all-in cash yield and integration capacity.
  • IRGA/Joday obligations, subsidiary liquidity and refinancing.

Each path represents a broad outcome region, not the probability of hitting an exact share price or IRR. Paths are a coarse approximation of a continuous joint distribution; the displayed downside and upside are not bounds. Joint driver dependencies must be considered, rather than multiplying marginal driver guesses. Scenario weights sum to 100% within this approximation. Severe outcomes remain possible outside the modeled paths.

Price movement alone does not change these weights. A changed causal premise, acquisition capacity, financial report or scenario definition does. Local assumption sensitivities suspend the researched weights until the full distribution is reassessed. No weighted-average IRR is presented as an expected shareholder return.

Method: Damodaran, chapter 33, printed pp.894-897. See valuation/model.json for machine-readable weights and docs/method/cash-flow-and-reinvestment.md for the capital definitions.

3 November 2026 review

The scenario definitions changed. The base purchase yield is now the measured CSU-group aggregate, deal capacity is capped at the observed pace with capacity growth of 0%/10%/15% by scenario, and unplaced cash is distributed. Weights are reassessed and kept: the downside adds a deployment stall that 2022–2025 history makes plausible; the base becomes more constrained; the upside loses better-than-record deal prices but requires capacity to scale with cash. None of this justifies a finer numerical revision. Neither the label comparison nor price movement changes odds.

3 November 2026 pipeline review

The full pipeline review changed no scenario definition or input. It found evidence on both sides of the existing weights: the profit pool (recurring maintenance, about 85% of EBITA) still grows outside Altera and deployment reached a record after the leadership change, supporting the base; returns on new capital have about halved since 2015 and common owners kept only about half of the consolidated cash growth, supporting a material downside weight. Neither shifts the coarse weights; 20/60/20 (5 years) and 30/50/20 (10 years) are kept. Q3 2026 results on 6 November are the next reassessment point.

3 November 2026 reference reconciliation

Scenario definitions changed (base organic growth 3%, upside 5%; acquired cohorts grow at each scenario's rate, so the downside's acquired businesses also erode at −2%; half-year deal cash; net-of-acquired-cash entry yield and capacity). The weights were reassessed and kept at 20/60/20 (5 years) and 30/50/20 (10 years). The base is now the evidence-weighted central path rather than a conservative one, which is what a 60% weight should describe; the downside still captures the AI-erosion and overpayment mechanisms with unchanged severity. The changes came from evidence on growth and timing, not from the investor labels' returns, and no weight was fitted to them.

3 November 2026 revenue rebuild

The scenarios are now stated as yearly revenue, margin and deal-price paths. The base path is slightly less favorable early (year-1 organic revenue 1.5%, young-cohort acquired margins) and the downside slightly more severe (margin deleverage). The outcome regions the weights describe are unchanged, so 20/60/20 and 30/50/20 are kept.

4 November 2026 yearly deal budget

Deployment is now a stated yearly budget: the base is the expected budget, anchored on the 2021-2025 through-cycle average with about 3% growth and no placed dips, the downside carries a two-year drought, and the upside keeps the record pace growing about 10%. These redefine where each path sits but not which business outcomes they represent; the weights stay 20/60/20 and 30/50/20. The weighted 5-year return (12.1%) now sits at the 12% hurdle.

Source bridge review — 5 November 2026

The revenue-to-cash coverage gap is closed. The June parent reporting window remains unchanged. The bridge now separates Synchronoss, DerbySoft, other H1 purchases, late-FY25 purchases, completed July Lumine businesses and other completed/open commitments. Latest Lumine Q3 owned sales update the forward missing-period estimates; the parent has not yet reported Q3. Gross consolidated sales are paired with common cash at specific 61.4% Lumine ownership where known, using the existing allocation estimate only for unsegmented pools. The same ownership now applies to known July cash/deferred reservations. Existing horizon-specific weights were reassessed and retained: the core joint demand/capital scenarios have not been replaced and exact numerical frequency evidence has not appeared. Synchronoss and July sales annualization are flat-quarter estimates; mature target cash margins are not reported owner cash. Undisclosed pool sales use matched net or gross capital/revenue prices with explicit timing assumptions. Open commitments are not labelled completed. Restricted subsidiary cash, the IRGA claim, customer attrition and target returns remain genuine risks. These are subjective estimates, not measured odds.

Q3 2026 review — 6 November 2026

Scenario definitions are unchanged; the September bridge changes inputs only. Weights are reassessed and kept at 20/60/20 (five years) and 30/50/20 (ten years).

For the base: recurring growth outside Altera held at 4% after FX, Altera's recurring decline narrowed to −8%, and nine-month net deal cash (USD1,986m) already exceeds the base full-year budget. For the downside: two US healthcare purchases with very high known attrition, DerbySoft at about 2.5x net closing cash per dollar of sales, a USD157m Q3 working-capital outflow that may or may not reverse, and IRGA up to USD1,295m. One quarter of steady recurring growth does not reduce the erosion risk the downside represents, and one strong deal year does not show the upside's sourcing scaling with cash. No weight was chosen with the return in view. Sources: csi-q3-2026-mda pp.4–5, 13, 17; csi-q3-2026-fs pp.10–15, 32.

Bull–bear review — Constellation Software, 5 November 2026

Subsequent source closure: the missing revenue bridge identified in this debate has now been completed. Current source-derived estimates, corrections and same-price/date effects. The original independent argument record below is retained with its information set; it is not a claim that all estimated target margins have become reported facts.

Independent advocates prepared opening cases without seeing the other draft, then exchanged point-by-point cross-examinations. A separate judge who did not author the prior model assessed the competing claims. Source reconstructions retain their stated provenance; inaccessible private reports were not newly read. Quoted sensitivities test arguments and are not automatically adopted forecasts.

Fixed quote CAD 3465.98, market time 2026-11-04T21:00:00.000Z; valuation date 2026-11-05. Original forecast exits retained.

HorizonBefore bear/base/bullAfter bear/base/bullWeighted before → after
5 years-2.75% / 11.83% / 21.36%-2.75% / 11.83% / 21.36%11.86% → 11.86%
10 years0.34% / 11.95% / 18.36%0.34% / 11.95% / 18.36%11.40% → 11.40%

Bull case

As of 5 November 2026. No opposing advocate draft was read. Existing company research, fact/calculation ledgers and exact registered source locators were examined; original issuer sources additionally checked live: Lumine Q3, CSU Q2, Diploma Q3 transcript, NVIDIA CFO commentary, TerraVest Highland/KBK, WOSG FY26. Harvia Q3 PDF retrieval failed; its registered extraction remains the evidence limit. Private source interpretations below are the repository's documented reconstruction, not a new claim to have read an unavailable private original.

The strongest bear case is slow portfolio-wide erosion while reported renewals temporarily mask migration, together with poorer large-deal economics and minority/redemption claims. Altera's recurring decline shows that switching costs are an economic question, not a guarantee.

CSU-B1 — Recurring cash deserves a less depressed organic path. Recurring maintenance supplies about 85% of EBITA; outside Altera it grew 4% in Q2. Retaining products that integrate workflows can sustain pricing and renewals without the cost of winning a new customer. Test the existing upside organic-growth path (2.5% year 1, 4% thereafter) against base1.5%→2%→3%. Sources csi-q2-2026, PDF pp.5–6 and supplemental operations pp.15–17; csi-fy2025, PDF pp.15–17. This is a conditional stronger path, not evidence that Altera has stabilised.

CSU-B2 — Supply, rather than cash, can recover faster. A decentralised sourcing network and the record TTM USD2.308bn net deployment make the upside budget plausible without new borrowing. Test only yearly.deploymentCapacity from the upside, retaining base purchase economics. Sources csi-q2-2026, acquisition note PDF pp.35–40; csi-fy2025, acquisition cash discussion PDF p.18; research/04-capital-allocation.md, through-cycle deployment calculations. The outside view is USD1.461bn 2021–25 average: a record window cannot establish the base. I defend upside capacity, not automatic full reinvestment.

CSU-B3 — A terminal premium can represent continued purchases. Test25× versus 20×, holding all operating paths. Specialised products, distributed capital allocation and a reconstructed 15.1% purchase yield can support value creation beyond exit (csi-2015-letter, pp.3–9; csi-2021-capital, pp.1–2; stage 6 measured cohort). But20× already requires approximately 19 post-exit years at 10% earnings growth, 15.1% reinvestment return and 9% required return before mature no-growth value. That is a duration sensitivity, not a forecast; 25× needs still longer. I cannot promote 25× from historical market multiples alone. Missing funded-cohort revenue and uncertain IRGA/fungibility remain surviving attacks.

Isolated shared-engine effects

Saved quote 3465.98; market timestamp 2026-11-04T21:00:00.000Z. Fixed valuation date 2026-11-05; model f681130ec4c1; exits remain the original model vintage. These are sensitivities, not joint forecasts or probability revisions. Baseline base IRR 11.83% / 11.95% (5/10 years).

ClaimExact input/path5-year base10-year baseChange, pp (5/10)
CSU-B1cases.base.inputs.yearly.organicGrowth12.86%12.69%+1.03 / +0.74
CSU-B2cases.base.inputs.yearly.deploymentCapacity14.59%14.90%+2.77 / +2.94
CSU-B3cases.base.inputs.exitMultiple16.68%14.17%+4.85 / +2.22

Bear case

Strongest opposing case

Thousands of specialist systems make replacement risky, recurring maintenance carries most of the profit, and recurring growth outside Altera was 4% in Q2. Decentralized acquisition and modest product spending have produced measurable cash returns across many deals, so AI headlines alone are insufficient to infer that this installed base will disappear.

Bear case

The current price already capitalizes much of that durability. At the saved quote the five-year base is approximately the 12% hurdle, before personal taxes or trading costs. The ownership bridge matters: common owners retain only part of consolidated growth after financing, minorities and the Topicus IRGA claim. USD1,307m of June cash sat in subsidiaries with restrictions, and IRGA wasUSD1,186m. A common-equity cash multiple must preserve those claims; the existence of accounting cash is not proof it can fund the next acquisition. [csi-q2-2026 PDF pp.13,15,17,54–59; csi-2021-ownership pp.2–3; valuation/calculations.json ownership/claims bridge.]

The outside view has deteriorated at the margin. The2021–2025 aggregate entry yield near 15% is materially below earlier bonus-basis corporate returns; those are different measures, yet both warn against carrying the small-deal era's exceptional economics to a larger capital base. CSU's2015 letter itself describes lower large-deal hurdles drawing behavior towards them. Altera recurring revenue fell 19% in Q2. It does not prove AI caused the decline, but it defeats the claim that all maintenance is immune. [csi-2015-letter pp.3–7; csi-fy2025 acquisition and Altera tables; csi-q2-2026 organic/Altera supplemental tables.]

The base assumes purchased cash margins rise 15→17.8%, organic growth returns to 3%, purchased revenue grows with it, and a20x exit. The latter requires roughly 6% growth beyond 2031 at the assumed 15.2% new-capital return and 9% required return. That is a perpetual value-driver assumption, not a specified ten- or twenty-year moat. Mature niche relationships can last a long time while the supply of attractive new targets still binds. The documented fall in net deployment from about 100% to 53% of cash by 2025 is direct evidence of this constraint. [research/05-thesis.md Exit multiple; research/07-assumption-register.md 4 November deal budget; csi-fy2021-mda p.15 and csi-fy2025 acquisition cash.]

Contested claims

  • CSU-B1 —At15x rather than 20x, cash generation does not provide the claimed margin of safety. The15x is the model's existing downside/no-expansion cross-check, not a prediction of market pricing.
  • CSU-B2 —New deals may earn Altera-like12% cash margins rather than converge to 17.8%. Keep current acquisitions and funding fixed to isolate execution risk.
  • CSU-B3 —One percentage point less annual organic and purchased-cohort growth tests replacement/customization spending and customer bargaining. Growth shortfall is plausible from the latest 1% group organic rate; it is not an asserted AI forecast.

No verified matched peer multiple or finite post-exit excess-return period exists in the current research. The issuer news index was reopened and still lists Q3 publication after close 6 November; there is no new CSU quarter to infer from Lumine's results. The September Lumine contribution does not update every subsidiary or the parent's full ownership bridge.

Shared-engine effects

Fixed saved quote CAD3465.98; market timestamp 2026-11-04T21:00:00.000Z; valuation date 5 November 2026; fixed original exit calendar. Base before: 11.83% / 11.95% (5/10years). These are one-change sensitivities to the base, except named bundles; existing scenario probabilities are not revised or claimed as validated.

ClaimChange5-year base IRR10-year base IRR5-year effect10-year effect
CSU-B1Exit15x5.93%9.22%-5.90pp-2.73pp
CSU-B2Acquired margin 12% throughout9.11%9.68%-2.72pp-2.27pp
CSU-B3Organic and acquired revenue growth 1point lower11.02%11.17%-0.81pp-0.78pp

Rebuttals

Bull response

5 November 2026. Written after independently frozen openings were exchanged. Every numbered bear claim is addressed below; original bull openings and sensitivities remain unchanged.

  1. Bear exit 15× versus 20×: concede duration risk; reject an automatic 15× central case. Source csi-q2-2026, PDFp17 confirms 4% recurring outside Altera and−19% Altera. It does not measure nineteen years of 10% future earnings growth. My20× duration diagnostic exposes, rather than verifies, the assumption. The bear's15× is also a chosen stress, not a transaction-backed present value. Keep15× adverse; demand a finite opportunity-backed terminal derivation before promoting a new central multiple. Neither own-history40× nor today's quote decides this.
  2. Bear acquired margin 12%: concede a surviving execution risk. Altera is an observed adverse example; the aggregate reconstructed 15.1% entry yield includes more than that one unit (csi-fy2022/2023/2025, acquisition notes; stage 6 cash/capital reconciliation). The base17.8% mature acquired margin is an estimated group convergence, not acquired-company guidance. I defend separate base/downside paths; do not assert 12% across every purchase from one troubled carve-out. My larger-budget bull survives only conditionally at maintained prices and margins.
  3. Bear organic/cohort growth−1point: partly rebut. Multiple years of positive recurring revenue and 4% outside Altera are evidence against generic negative portfolio growth today (csi-q2-2026, p17; csi-fy2025, recurring tables). They cannot guarantee future pricing or retention. The one-point stress is useful, not independently established as the most likely path. My4% upside remains upside, not upgraded base.
  4. Claims, restricted cash and record-deal-window attacks: concede. No claim is removed, no announced pool is relabelled closed, no restricted cash is released in my sensitivities. The USD2.308bn record cannot establish repeatable seller supply at 15% yield. The larger-budget claim is a conditional option, not a central upgrade. Missing known-cohort sales, IRGA growth and funding fungibility remain unresolved; conviction is moderate, not high.

Bear response

5 November 2026, after independent openings were exchanged.

  1. Bull recurring 4% path: partly rebutted. Q2 outside-Altera recurring 4% and the multi-year installed-base record support durability (csi-q2-2026, supplemental operations pp.15–17; csi-fy2025, revenue tables). I concede they do not establish a central negative portfolio path. They also do not establish 4% for every future year or permanent margin. Altera's observed decline proves differentiated customer/unit analysis is necessary, not that every product is being displaced by AI. Keep4% as upside and 1point lower growth as sensitivity.
  2. Bull larger sourcing budget: conditional, not a central revision. RecordTTM2.308bn is real acquisition spending, but 2021–2025 net average 1.461bn and declining cash deployment are the outside view. New supply at maintained returns must be demonstrated separately (csi-fy2021-mda p.15; csi-fy2025 acquisition cash; csi-q2-2026 acquisition note). The bull concedes this. Likewise I concede one troubled carve-out cannot make 12% acquired margins the new central level; the aggregate 15.1% entry yield is evidence for the present conditional base.
  3. Bull20/25x continuation: central uncertainty survives. A19year10%-growth diagnostic is a burden, not a measured advantage life. The bull concedes no matched peer cash table and no sourced finite duration. A15x stress exposes dependence but is not uniquely established as central. No mechanical cut to 15x is warranted solely because it lowers shareholder returns. Current20x needs explicit duration/risk disclosure; 25x remains upside sensitivity.
  4. Bear claims defended or conceded. CSU-B1 retained as stress, not central verdict. CSU-B2 retained as execution downside; central 12% conceded unproven. CSU-B3 retained as one-point growth stress; evidence does not select it centrally. IRGA, restricted cash and ownership claims remain actual underwriting constraints, not removed in either case (csi-q2-2026 pp.13,15,17,54–59). The next 6 November group quarter must be reconciled before an operating revision; Lumine alone does not establish a new whole-group bridge.

Conviction is moderate in product retention, lower in exact deployment, acquired margins and terminal duration; current base at about 12% offers little margin of safety. No supported current numerical change was established by these exchanged arguments.

Judgment

Existing estimates receive no presumption merely because they are already in the model. Positive company evidence, the relevant outside view and the capital/funding bridge determine each verdict; neither arbitrary conservatism nor an unsupported favorable sensitivity replaces it. The evidence and reconstruction below explain numerical changes or explicit no-change conclusions claim by claim.

Contested claimVerdictEvidence/locatorReason and model action
bull advocate: CSU-B1: cases.base.inputs.yearly.organicGrowthrejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. Recurring ex-Altera Q2 growth 4% and FY2025 maintenance support a positive but modest base; no evidence Altera stabilizes enough for upside 4% portfolio growth.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bull advocate: CSU-B2: cases.base.inputs.yearly.deploymentCapacityrejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. Long-run average deployment and observed decline in cash deployment support capped central budgets; latest record spending supports an upside, not permanent central sourcing.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bull advocate: CSU-B3: cases.base.inputs.exitMultiplerejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. Decentralized purchases and measured 15.1% cash yield support a conditional premium, but 20x entails roughly 19 post-exit years at 10%growth/15.1%return/9%requiredreturn; 25x is not substantiated.Reconstructed the isolated proposed input/path from independent opening and shared engine, at frozen saved quote/date/horizons; source mechanism separated from unsupported numerical extrapolation.
bear advocate: CSU-B1: Exit15xrejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. 15x sizes shorter runway; the niche renewal base and measured acquisition value creation support retaining a premium conditionally, not a no-runway central case.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.
bear advocate: CSU-B2: Acquired margin 12% throughoutrejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. Altera deterioration is a real adverse observation, but its 12% scenario cannot represent every future target when matched multi-deal evidence supports higher acquired margins.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.
bear advocate: CSU-B3: Organic and acquired revenue growth 1point lowerrejectcsi-q2-2026 PDF pp.5–6,13,15–17,35–40,54–59; csi-fy2025 acquisition/Altera supplemental tables; csi-2015-letter pp.3–9. Latest weak organic growth warrants the modest recovery already central; one-point erosion remains downside because ex-Altera maintenance still grew 4%.Reconstructed the independent isolated stress at the same quote/date/horizons; do not treat stress size as a probability or a measured current fact.

Retain existing coarse horizon-specific weights after reassessment: scenarios already represent these adverse/favorable operating mechanisms. Numerical odds are subjective, not verified frequencies; unresolved gaps prevent high conviction. No tuning to return.

Conviction

Low to moderate; recurring product economics supported, current ownership/funding and full revenue bridge incomplete. These are forward estimates with surviving attacks, not confirmed outcomes. Neither numerical calibration, a completed checklist nor passing software tests establishes investment skill. Reported facts stay separate from forward judgments, and adverse paths are not worst-case bounds.

What would change the view: 6 November Q3: Altera maintenance, ex-Altera recurring growth, gross acquisition consideration, restricted subsidiary cash and IRGA claims.

Exact inputs, isolated sensitivities, model hashes and same-price/date before/after returns.

Q3 2026 outcome of the named evidence — 6 November 2026

The debate named five Q3 observations. Results, from the Q3 MD&A and statements:

Named evidenceQ3 2026Bearing on the debate
Altera maintenanceRecurring −8% (Q2 −19%), nine months −11%; total organic −18%; departures expected through the end of 2027Decline continuing but narrower; supports the base's Altera drag, not a recovery
Recurring growth outside Altera+4% in Q3 and over nine monthsThe bull premise held for another quarter; CSU-B3's one-point erosion stays a stress
Gross acquisition consideration9M total 2,305; post-September pool 673Supply did not dry up in 2026; DerbySoft's high price supports CSU-B2's caution on large deals
Restricted subsidiary cash1,025 (June 1,307)Less trapped cash, still material
IRGA claim1,295 (June 1,186); 741 currentGrew 9% in a quarter: €63m of the €102m rise came from the Asseco share price, the rest from Topicus maintenance revenue and net assets

No contested claim changes verdict. At C$3,511.69 on 6 November the five-year base is 12.18% (before the roll: 11.56%), still about the 12% hurdle; the gain comes almost entirely from adding back the 9M working-capital outflow (07-assumption-register.md).

Public source library

Primary filings, investor communications, and industry evidence.

primary

CSU Q2 2026 shareholder report and interim financial statements ↗

PDF pp. 13 FCFA2S; 15 ownership cash; 17 liquidity; 27 balance sheet; 32 cash flows; 35–40 acquisitions; 42–44 investments; 46–50 debt; 52 financing and shares; 54 claims; 55–59 NCI and subsequent events. Printed page numbers are one lower.

Published Aug 11, 2026 · Reviewed Oct 27, 2026
primary

CSU FY2025 shareholder report and audited financial statements ↗

PDF pp. 4 results; 10 IRGA and cash income; 13 FCFA2S; audited cash flows, note 4 acquisitions, note 18 financing, note 26 working capital. Printed page numbers are one lower. Also: PDF p.4 income summary; 5-6 revenue by type, staff by department; 13 FCFA2S reconciliation; 15-17 Topicus/Lumine and Altera supplemental tables; 18 liquidity and net cash flows; 38 balance sheet; 43 cash flows; 59-61 acquisitions (Cipal Schaubroeck 258, others 1,321); 69 intangible cost and goodwill; 93-94 operating segments and geography.

Published Mar 9, 2026 · Reviewed Oct 27, 2026
primary

CFO explanation of Topicus deemed ownership and IRGA ↗

PDF pp. 2–3: accounting assumes eventual ownership of Joday shares because the purchase obligation is recognized as a liability. This is not actual economic ownership today.

Published Sep 17, 2021 · Reviewed Oct 27, 2026
primary

Mark Leonard: 2015 president’s letter ↗

PDF pp. 3–7: scale, capital returns, magnetic hurdles, organic investment and decentralization; p. 9 maintenance growth decomposition. Historical framework, not a current forecast.

Published Apr 26, 2016 · Reviewed Oct 27, 2026
primary

Appointment of Daan Dijkhuizen as Chief AI Officer ↗

AI-native VMS investment through VMS Ventures, product and internal applications, and operating-group knowledge sharing; an initiative, not demonstrated incremental profit.

Published Oct 21, 2026 · Reviewed Oct 27, 2026
primary

CSU Q3 2026 results and call timetable ↗

Results after TSX close on 6 November 2026; call 9 November at 8 AM ET. Read the dated release: the unsuffixed URL is an old 2014 announcement.

Published Oct 16, 2026 · Reviewed Oct 27, 2026
primary

CSU issuer news index ↗

Coverage through 27 October: 21 October AI appointment, 16 October reporting timetable, 31 August board resignation, 11 August results, June acquisitions. No Q3 results published on the index.

Reviewed Oct 27, 2026
primary

Roper Q3 2026 results ↗

Opening operating highlights and acquisition discussion; +7% organic revenue and $436m bolt-on spending. Peer context, not CSU guidance or a comparable valuation denominator.

Published Oct 22, 2026 · Reviewed Oct 27, 2026
market data

CSU.TO delayed closing quote ↗

Chart API: CAD 3,361.46 at 20:00:01 UTC. Cross-checked against the TSX close on Stock Analysis. Runtime quote remains separate from operating assumptions.

Published Oct 26, 2026 · Reviewed Oct 27, 2026
primary

CSU FY2022 shareholder report ↗

PDF p.6 organic growth; p.18 cash used in acquisitions. Also: Altera purchase (727, contributed revenue 556, pro forma 6,912), other 2022 deals 1,148; cash flow statement (2022 and 2021 columns); FCFA2S reconciliation PDF p.14.

Reviewed Nov 3, 2026
primary

CSU FY2023 shareholder report ↗

PDF p.5 organic growth; p.18 cash used in acquisitions. Also: WideOrbit (504, revenue 147, pro forma 8,432), Optimal Blue (705, revenue 53, pro forma 8,541), other 2023 deals 1,400; Altera supplemental (revenue 810, FCFA2S 94); cash flow statement (2023 and 2022 columns).

Reviewed Nov 3, 2026
primary

CSU 2026 management information circular ↗

Printed pp.11 share count and no >10% holder; 12-14 bonus plan (ROIC on Average Invested Equity Capital net of a 5% rate, net revenue growth, 75% of after-tax bonus into shares escrowed about four years, no anti-hedging policy); 14 Leonard/Miller salary waivers and five-year TSR (106% vs TSX 111%); 15-16 summary compensation; 21-22 director holdings at 28 March 2026; board independence (7 of 9 nominees).

Published Mar 31, 2026 · Reviewed Nov 3, 2026
market data

CSU.TO and USD/CAD monthly price and volume history ↗

Yahoo chart API, retrieved 3 Nov 2026: December closes 2015-2025, monthly volumes Dec 2024-Oct 2026, 52-week range C$2,196-3,605, intraday C$3,397.23 on 3 Nov 2026; CAD=X December closes. Unadjusted for the January 2021 Topicus spin-out. Delayed quote, not an operating input.

Published Nov 3, 2026 · Reviewed Nov 3, 2026
primary

CSU Q3 2026 interim financial statements (interim financial report) ↗

36 PDF pages. p.2 financial position; p.3 income; p.7 cash flows (reconciles 3,089 + 2,092 − 431 − 2,037 − 20 = 2,693); pp.10–17 note 4 acquisitions (Synchronoss pp.10–11, DerbySoft pp.11–13, additional 1,605 pp.13–15, provisional 2,385 p.14); p.18 Asseco; p.20 note 6 other assets/liabilities; p.30 fair values; p.31 contingent consideration; p.32 note 17 working capital and note 18 ownership; p.33 NCI balances.

Published Nov 6, 2026 · Reviewed Nov 6, 2026
primary

CSU Q3 2026 management discussion and analysis (Q3 shareholder report) ↗

26 PDF pages. p.3 results table; pp.4–5 organic growth by type and quarter, FX-adjusted, US healthcare and Altera recurring table; pp.6–8 expenses; pp.9–10 IRGA; p.12 finance costs; p.13 FCFA2S reconciliation; p.14 quarterly results; pp.14–16 Topicus/Lumine supplemental tables; pp.16–17 Altera supplemental tables; p.18 PEMS and liquidity; p.19 cash-flow summary; pp.20–23 debt and IRGA; p.23 contractual obligations; p.26 subsequent events.

Published Nov 6, 2026 · Reviewed Nov 6, 2026
competitor primary

Tyler Technologies Q3 2026 earnings release, SEC Exhibit99.1 ↗

Complete operating highlights/outlook and financial reconciliations read, pp.1-3,6-10. Recurring sales growth, payment-contract wind-down, working-capital cash, share compensation and acquisition spend are separate. Peer demand and competing capital, not a measurement of CSU’s retention, seller pool or cash margin. Recovered earlier source-access gap via the original SEC exhibit.

Published Oct 28, 2026 · Reviewed Nov 8, 2026
secondary

CSU 9 November Q3 call: public transcription of management remarks ↗

Full presentation/Q&A read, not the automated headline summary. Working-capital Q&A, acquisition-margin/timing Q&A and Paul Treiber IRGA question. Third-party transcription with speaker-attribution discrepancies; issuer audio was not reviewed. No numerical financial fact is bound from it; signed revised settlement terms and working-capital amounts remain unverified.

Published Nov 9, 2026 · Reviewed Nov 9, 2026
secondary

CSU Q3 2026 call: second public transcription, IRGA section ↗

IRGA question/answer cross-check only. Repeated transcripts can share a feed and are not independent confirmation. Primary webcast page resolves but exposes only a JavaScript player to the text reader.

Published Nov 9, 2026 · Reviewed Nov 9, 2026